

Supporting Information

Synthesis and Structure–Activity Relationship (SAR) Studies of 1,2,3-Triazole, Amide, and Ester-Based Benzothiazole Derivatives as Potential Molecular Probes for Tau Protein

Hendris Wongso,^{a,b,c} Maiko Ono,^d Tomoteru Yamasaki,^e Katsushi Kumata,^e Makoto Higuchi,^d Ming-Rong Zhang,^e Michael J. Fulham,^f Andrew Katsifis,^{*f} Paul A. Keller^{*a}

^aSchool of Chemistry and Molecular Bioscience, Molecular Horizons, University of Wollongong, Wollongong, NSW 2522, Australia

^bResearch Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, National Research and Innovation Agency, Pusiptek, Banten 15314, Indonesia.

^cResearch Collaboration Center for Theranostic Radiopharmaceuticals, National Research and Innovation Agency, Sumedang 45363, Indonesia

^dDepartment of Functional Brain Imaging, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.

^eDepartment of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.

^fDepartment of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia

Table of Contents

1. General experimental information	S3
2. Synthesis of 1,2,3-triazole, amide, and ester derivatives	S4
General procedure A	S4
General procedure B	S4
General procedure C	S5
General procedure D	S5
Compounds 35-39	S5-S7
Compounds 41-43	S7-S8
Compounds 54-63	S9-S11
Compounds 64-78	S11-S17
Compounds 84-88	S18-S19
Compounds 89-93	S19-S21
Compounds 109-121	S21-S27
Compound 122	S27
Compounds 127-130	S27-S29
3. ^1H NMR and ^{13}C NMR spectra of final compounds	S30-S69
4. ^1H NMR and ^{13}C NMR spectra of key intermediates	S70-S89
5. HRMS spectra of final compounds	S90-S125
6. Physicochemical properties of several ligand candidates	S126-S128
7. References	S129

1. General Experimental Information

Unless stated otherwise, all chemicals were laboratory or reagent grade and were purchased from Merck (Australia) or AK Scientific, Inc (USA). All chemicals were used as received. All solvents were reagent grade and, when necessary, were purified and dried by standard methods. Water was purified via Millipore filtration prior to use. HOBT was purchased with added stabilizer (10% w/w H₂O), and therefore, the quantity required for reactions was adjusted accordingly and is reflected in the reagent mass reported in the experimental. All reactions requiring anhydrous conditions were conducted under a positive atmosphere of nitrogen in oven-dried glassware. Cold reaction temperatures were obtained by an ice bath (0 °C). Heating of reaction was performed with a paraffin oil bath. Standard syringe and autopipette techniques were used for the anhydrous addition of liquids. Reactions were routinely monitored by TLC analysis performed on aluminium-backed SiO₂ gel plates (F254 grade – 0.20 mm thickness) or by low resolution mass spectrometry (LRMS) on Shimadzu LC-2010 mass spectrometer. Visualization on TLC plates was achieved with UV light ($\lambda = 254, 365$ nm), ninhydrin stain, or cerium ammonium molybdate stain. All filtrations were conducted as a gravity filtration through a filter paper Whatman Grade 4 (20 – 25 μm) or as a vacuum filtration through a sintered glass funnel (medium porosity). Vacuum filtration was achieved with the aid of vacuum pump. Organic solutions were dried over anhydrous Na₂SO₄. Solvent removal via concentration was performed on a rotary evaporator under reduced pressure. All solvent mixtures are expressed in terms of volume ratio (i.e. v/v). Normal phase flash column chromatography was performed on SiO₂ gel 60 with a positive air pressure. Preparative TLC was run using PLC silica gel 60 F₂₅₄ 1 mm plates (20 x 20 cm²). All synthesized compounds were dried under high vacuum (< 1 mbar) before determination of chemical yields and spectroscopic characterization. All synthesized compounds were subjected to full spectroscopic characterization and assignment. Melting points were determined on a Gallenkamp melting point apparatus in open capillary tubes and were uncorrected. ¹H and ¹³C NMR spectra were recorded on a Bruker Avance 400 (400 MHz) or Varian Inova 500 (500 MHz) NMR spectrometer. Chemical shifts (δ) were reported in parts per million (ppm) relative to the internal standard. Samples were dissolved in CDCl₃ (with TMS as the internal standard – 0.00 ppm), CD₃OD (solvent resonance as internal standard – 3.31 ppm) or DMSO-*d*₆ (solvent resonance as internal standard – 2.50 ppm). ¹³C NMR signal assignments were confirmed by analysis of NMR experiments: APT, gCOSY, gHSQC, gHMBC, zTOCSY, NOESY and/or gHSQC-TOCSY. Low resolution mass spectrometry (LRMS) spectra were recorded on a

Shimadzu LC-2010 mass spectrometer in electrospray positive and negative ionization modes (ESI-MS). High resolution mass spectrometry (HRMS) spectra were recorded on a Waters Quadrupole-Time of Flight (QTOF) Xevo spectrometer in electrospray positive and negative ionization modes (ESI-MS). All mass spectrometry samples were dissolved in HPLC grade MeOH. Solid-state infrared spectroscopy was performed on a Bruker Vertex 70 FTIR spectrometer in combination with a MIRacle 10 Single Reflection Attenuated Total Reflectance accessory outfitted with a 1.5 mm round diamond crystal. IR peaks are reported as the wavenumber (cm^{-1}) of the maximum absorption. Analytical HPLC was performed on a Shimadzu LC-2030C 3D UV/vis detector ($\lambda = 254$ nm) using a C-18 column (5 μm , 4.9 x 150 mm) at 25 °C using mobile phases A (water and 0.1% trifluoroacetic acid (TFA)) and B (MeCN and 0.1% TFA) at a flow rate of 1 $\text{mL}\cdot\text{min}^{-1}$. The following gradient was applied: gradient elution for 35 min at 0 – 100% of solvent B, linear increase from 0 – 100% of solvent B over 25 min, hold at 100% of solvent B for 10 min (tau ligands). The purity of all final compounds was found to be higher than 95%.

2. Synthesis of 1,2,3-Triazole, Amide, and Ester Derivatives

General Procedure A: Synthesis of 1,2,3-triazole product (CuAAC reaction)

General Procedure A₁: To a stirred solution of alkyne (1.0 eq) in *t*-BuOH/H₂O (1:1, 20 mL/mmol alkyne) was added CuSO₄·5H₂O (0.1 eq), sodium ascorbate (0.2 eq), and the appropriate azide (2.0 eq). Stirring was prolonged at rt for 24 h under N₂ atmosphere, and the resulting reaction mixture was poured into H₂O (25 mL), and extracted with EtOAc (3 x 25 mL). The organic solution was separated, washed with H₂O (2 x 25 mL), brine (2 x 25 mL), dried (Na₂SO₄), filtered, and concentrated. The residue was purified by preparative TLC plate chromatography to afford the 1,4-disubstituted-1,2,3-triazole product.

General Procedure A₂: To a stirred solution of alkyne (1.0 eq) in *t*-BuOH/H₂O (1:1, 20 mL/mmol alkyne) was added CuSO₄·5H₂O (0.1 eq), sodium ascorbate (0.2 eq), and the appropriate azide (2.0 eq). Stirring was prolonged at rt for 24 h under N₂ atmosphere, and the resulting precipitate was filtered. The residue was triturated with sequential addition of CH₂Cl₂, MeCN, and hot MeOH to afford the 1,4-disubstituted-1,2,3-triazole product.

General Procedure B: Azidation of alkyl bromide

The appropriate alkyl bromide or benzyl bromide or phenylethyl bromide (1.0 eq) and NaN₃ (1.5 eq) were combined in anhydrous DMF (20 mL), and stirred at 55 °C for 24 h. The resulting

reaction mixture was poured into H₂O (25 mL) and extracted with CH₂Cl₂ (3 x 25 mL). The organic layer was washed with H₂O (2 x 25 mL), brine (2 x 25 mL), dried (Na₂SO₄), filtered, and concentrated. The azide product was used for the next reaction without further purification (alkyl azide) or purified by flash chromatography (benzyl azide and phenylethyl azide) over SiO₂ gel (CH₂Cl₂/MeOH).

General Procedure C: Amide Coupling

The acid (1.0 eq), the appropriate aromatic amine (1.0 eq), HOBT (1.0 eq), EDCI (1.3 eq), and DIPEA (4.0 eq) were combined in anhydrous DMF (10 mL/mmol), and stirred at rt for 24 h under N₂ atmosphere. The resulting reaction mixture was poured into H₂O (50 mL), and extracted with EtOAc (3 x 50 mL). The organic layer was washed with H₂O (2 x 50 mL), brine (2 x 50 mL), dried (Na₂SO₄), filtered, and concentrated. The residue was purified by preparative TLC plate chromatography to afford the desired amide product.

General Procedure D: Ester Formation

The benzothiazole salt (1.0 eq) and the appropriate alkyl bromide (1.0 eq) were combined in anhydrous DMF (10 mL/mmol), and stirred at rt for 24 h under N₂ atmosphere. The resulting reaction mixture was poured into H₂O (50 mL), and extracted with EtOAc (3 x 50 mL). The organic layer was washed with H₂O (2 x 50 mL), brine (2 x 50 mL), dried (Na₂SO₄), filtered, and concentrated. The residue was purified by preparative TLC plate chromatography to afford the desired ester product.

2-aminobenzo[*d*]thiazol-6-ol 35.¹ To a stirred solution of thiourea **34** (7.60 g, 0.10 mol) in EtOH (200 mL) and concentrated HCl (9.0 mL) was added a hot solution of 1,4-benzoquinone **33** (21.60 g, 0.20 mol) in EtOH (400 mL). The mixture was stirred at rt for 48 h. The solvent was evaporated, and the residue triturated with hot MeCN (100 mL). This process was repeated until TLC analysis of the solid showed only one component. The solid was collected and washed with cold EtOH (10 mL) to afford the product as the hydrochloride salt. The free base was obtained by dissolving the salt in a minimal volume of H₂O, followed by neutralisation using NaOAc. The resulting precipitated was collected by filtration, yielding the hydroxy benzothiazole **35** (12.05 g, 72%) as a dark grey solid. The spectroscopic data was in agreement with that previously reported. TLC (CH₂Cl₂/MeOH – 90:10): R_f = 0.41. ¹H NMR (400 MHz, CD₃OD) δ 7.20 (d, *J* = 8.8 Hz, 1H), 7.01 (d, *J* = 2.4 Hz, 1H), 6.73 (dd, *J* = 8.8, 2.4 Hz, 1H).

¹³C NMR (400 MHz, CD₃OD) δ 164.4, 152.6, 146.1, 132.3, 118.6, 114.0, 107.4. MS (ESI +ve) *m/z* 167 ([M + H]⁺, 100%).

6-((*tert*-butyldimethylsilyl)oxy)benzo[*d*]thiazol-2-amine 36. To a stirred solution of hydroxy benzothiazole **35** (5.00 g, 30.1 mmol) in anhydrous DMF was added TBDMS-Cl (5.40 g, 36.1 mmol) and imidazole (2.46 g, 36.1 mmol). The reaction was stirred at rt for 24 h, and partitioned between H₂O (150 mL) and EtOAc (150 mL). The aqueous phase was extracted with EtOAc (2 x 100 mL), and the combined organic layers dried (Na₂SO₄), filtered, and concentrated. The residue was subjected to flash chromatography over SiO₂ gel (EtOAc/hexanes – 30:70) to afford the protected phenol **36** (0.35 g, 41%) as a reddish oil. The spectroscopic data was in agreement with that previously reported. TLC (EtOAc/hexanes – 30:70): R_f = 0.57. ¹H NMR (400 MHz, CDCl₃) δ 7.35 (d, *J* = 8.4 Hz, 1H), 7.05 (d, *J* = 2.4 Hz, 1H), 6.80 (dd, *J* = 8.4, 2.4 Hz, 1H), 5.85 (br s, 2H), 0.98 (s, 9H), 0.19 (s, 6H). ¹³C NMR (400 MHz, CDCl₃) δ 165.2, 151.2, 146.5, 132.2, 119.2, 118.9, 112.0, 25.8, 18.3, -4.67. MS (ESI +ve) *m/z* 281 ([M + H]⁺, 100%). HRMS (ESI +ve TOF) calcd for C₁₃H₂₁N₂OSSi⁺ 281.1138, found 281.1138 ([M + H]⁺).

6-((*tert*-butyldimethylsilyl)oxy)-2-iodobenzo[*d*]thiazole 37. To a solution of protected phenol **36** (0.52 g, 1.86 mmol) and *p*-toluenesulfonic acid monohydrate (1.12 mg, 6.51 mmol) in MeCN (55 mL) was added a solution of NaNO₂ (0.26 g, 3.72 mmol) and KI (0.80 g, 4.83 mmol) in H₂O (2.0 mL) at 0 °C. The reaction was allowed to reach rt, and was stirred for 18 h. The reaction mixture was quenched with H₂O (100 mL) and basified with 2 M NaHCO₃ to pH 8-9, followed by addition of Na₂S₂O₃ (10 mL), yielding a brown precipitate. The precipitate was collected by filtration, washed with H₂O (20 mL), and dried *in vacuo*. The residue was subjected to flash chromatography over SiO₂ gel (EtOAc/hexanes – 30:70) to afford the iodobenzothiazole **37** (0.46 g, 63%) as a grey solid. TLC (EtOAc/hexanes – 30:70): R_f = 0.69. Mp 68 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, *J* = 8.4 Hz, 1H), 7.26 (d, *J* = 2.4 Hz, 1H), 6.94 (dd, *J* = 8.4, 2.4 Hz, 1H), 1.00 (s, 9H), 0.22 (s, 6H). ¹³C NMR (400 MHz, CDCl₃) δ 154.3, 149.6, 140.3, 123.0, 120.2, 110.7, 102.2, 25.8, 18.4, -4.28. IR (neat) ν_{max} 2954 (m), 2924 (m), 2852 (m), 1595 (m), 1555 (m), 1468 (s), 1438 (s), 1401 (m), 1360 (w), 1269 (s), 1252 (s), 1210 (s), 1004 (m), 928 (s), 834 (s), 780 (s) cm⁻¹. MS (ESI +ve) *m/z* 392 ([M + H]⁺, 100%). HRMS (ESI +ve TOF) calcd for C₁₃H₁₉INOSSi⁺ 391.9996, found 391.9997 ([M + H]⁺).

6-((*tert*-butyldimethylsilyl)oxy)-2-((trimethylsilyl)ethynyl)benzo[*d*]thiazole 38. To a solution of iodobenzothiazole **37** (200 mg, 0.51 mmol), PdCl₂(PPh₃)₂ (10 mg, 0.01 mmol), CuI (3 mg, 0.02 mmol), and triethylamine (0.46 mL, 3.30 mmol) in anhydrous DMF (2.0 mL) was added a solution of ethynyltrimethylsilane (100 mg, 1.02 mmol). The resulting mixture was stirred at 65 °C for 6 h. After cooling to rt, the solution was filtered through a layer of Celite, and concentrated. The residue was subjected to flash chromatography over SiO₂ gel (EtOAc/hexanes – 20:80) to afford the protected alkyne **38** (136 mg, 74%) as a brown oil. The product was used in the next reaction step immediately or stored in the freezer for a limited time due to stability issues. TLC (EtOAc/hexanes – 20:80): R_f = 0.86. ¹H NMR (400 MHz, CDCl₃) δ 7.88 (d, J = 8.5 Hz, 1H, H4), 7.25 (d, J = 2.5 Hz, 1H, H7), 7.01 (dd, J = 8.5, 2.5 Hz, 1H, H5), 1.00 (s, 9H, H2''), 0.30 (s, 9H, H3'), 0.22 (s, 6H, H1''). ¹³C NMR (400 MHz, CDCl₃) δ 155.0, 147.8, 146.2, 137.0, 124.3, 120.9, 112, 102.5, 97.1, 25.8, 18.4, -0.38, -4.25. IR (neat) ν_{max} 2912 (m), 1610 (m), 1552 (m), 1461 (s), 1438 (s), 1404 (m), 1366 (w), 1289 (s), 1111 (m), 930 (s), 844 (s), 788 (s) cm⁻¹. MS (ESI +ve) m/z 362 ([M + H]⁺, 100%). HRMS (ESI +ve TOF) calcd for C₁₈H₂₈NOSSi₂⁺ 362.1425, found 362.1426 ([M + H]⁺).

2-ethynylbenzo[*d*]thiazol-6-ol 39. To a solution of the protected alkyne **38** (110 mg, 0.30 mmol) in MeOH (5.0 mL) was added KF (220 mg, 3.78 mmol), and the mixture was stirred at rt for 4 h. The solvent was removed, and the residue was purified by preparative TLC plate chromatography (CH₂Cl₂/MeOH – 90:10) to afford the free alkyne **39** (45 mg, 86%) as a pale yellow solid. TLC (CH₂Cl₂/MeOH – 90:10): R_f = 0.10. Mp 101 °C (decomp). ¹H NMR (500 MHz, DMSO) δ 10.14 (s, 1H), 7.85 (d, J = 8.5 Hz, 1H), 7.74 (d, J = 2.5 Hz, 1H), 7.22 (dd, J = 8.5, 2.5 Hz, 1H), 4.33 (s, 1H). ¹³C NMR (500 MHz, DMSO) δ 157.0, 145.7, 143.2, 136.3, 124.2, 117.0, 106.4, 87.1, 77.0. IR (neat) ν_{max} 3310 (w), 2977 (w), 2188 (w), 2134 (w), 1732 (s), 1615 (w), 1589 (w), 1530 (m), 1480 (m), 1450 (m), 1394 (m), 1370 (m), 1254 (s), 1153 (s), 1097 (s), 1030 (m), 798 (m), 761 (m) cm⁻¹. MS (ESI +ve) m/z 174 ([M – H]⁻, 100%). HRMS (ESI –ve TOF) calcd for C₉H₄NOS⁻ 174.0019, found 174.0019 ([M – H]⁻).

2-iodo-6-methylbenzo[*d*]thiazole 41. To a solution of 6-methylbenzo[*d*]thiazol-2-amine **40** (4.11 g, 25.00 mmol) and *p*-toluenesulfonic acid monohydrate (15.07 g, 87.50 mmol) in MeCN (150 mL) was added a solution of NaNO₂ (4.45 g, 50.00 mmol) and KI (10.79 g, 65.00 mmol) in H₂O (16 mL) at 0 °C. The reaction was allowed to reach rt, and was stirred for 18 h. The reaction mixture was quenched with H₂O (350 mL) and basified with 2 M NaHCO₃ to pH 8-9, followed by addition of Na₂S₂O₃ (20 mL), yielding a light brown precipitate. The precipitate

was collected by filtration, washed with H₂O (20 mL), and dried *in vacuo* to afford the iodobenzothiazole **41** (4.90 g, 71%) as a light orange solid. The product was used directly for the next step without further purification. TLC (EtOAc/hexanes – 60:40): R_f = 0.88. Mp 96 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.89 (d, J = 8.4 Hz, 1H), 7.60 (br s, 1H), 7.23 (dd, J = 8.4, 1.6 Hz, 1H), 2.46 (s, 3H). ¹³C NMR (400 MHz, CDCl₃) δ 152.6, 139.4, 136.0, 128.0, 122.1, 120.3, 104.3, 21.6. IR (neat) ν_{max} 2910 (w), 1886 (w), 1609 (m), 1505 (m), 1428 (m), 1394 (m), 1307 (m), 1232 (m), 1056 (m), 1042 (w), 954 (s), 875 (m), 854 (m), 807 (s), 584 (s). MS (ESI +ve) m/z 276 ([M + H]⁺, 100%). HRMS (ESI +ve TOF) calcd for C₈H₇INS⁺ 275.9338, found 275.9344 ([M + H]⁺).

6-methyl-2-((trimethylsilyl)ethynyl)benzo[d]thiazole 42. To a solution of iodobenzothiazole **41** (1.76 g, 6.40 mmol), PdCl₂(PPh₃)₂ (90 mg, 0.13 mmol), CuI (26 mg, 0.14 mmol), and triethylamine (4.0 mL, 28.70 mmol) in anhydrous DMF (8.0 mL) was added a solution of ethynyltrimethylsilane (1.26 g, 12.83 mmol). The resulting mixture was stirred at 65 °C for 6 h. After cooling to rt, the solution was filtered through a layer of Celite, and concentrated. The residue was subjected to flash chromatography over SiO₂ gel (EtOAc/hexanes – 60:40) to afford the protected alkyne **42** (1.21 g, 76%) as a light yellow oil. The product was used in the next reaction step immediately or stored in the freezer for a limited time due to stability issues. TLC (EtOAc/hexanes – 60:40): R_f = 0.89. ¹H NMR (400 MHz, CDCl₃) δ 7.91 (d, J = 8.4 Hz, 1H), 7.62 (br s, 1H), 7.30 (dd, J = 8.4, 1.6 Hz, 1H), 2.48 (s, 3H), 0.30 (s, 9H). ¹³C NMR (400 MHz, CDCl₃) δ 151.0, 147.3, 136.9, 135.6, 128.5, 123.3, 121.1, 102.7, 97.1, 21.7, 0.40. IR (neat) ν_{max} 3215 (br), 2990 (w), 1608 (m), 1558 (m), 1493 (m), 1439 (m), 1384 (m), 1302 (m), 1211 (s), 1109 (m), 1053 (m), 922 (s), 877 (s), 708 (m). MS (ESI +ve) m/z 246 ([M + H]⁺, 100%). HRMS (ESI +ve TOF) calcd for C₁₃H₁₆NSSi⁺ 246.0767, found 246.0767 ([M + H]⁺).

2-ethynyl-6-methylbenzo[d]thiazole 43. To a solution of the protected alkyne **42** (0.94 g, 3.83 mmol) in MeOH (30 mL) was added KF (1.00 g, 17.21 mmol), and the mixture was stirred at rt for 2 h. The solvent was removed, and the residue was subjected to flash chromatography over SiO₂ gel (EtOAc/hexanes – 60:40) to afford the free alkyne **43** (0.64 g, 96%) as a pale yellow solid. TLC (EtOAc/hexanes – 60:40): R_f = 0.77. Mp 60 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, J = 8.4 Hz, 1H), 7.65 (br s, 1H), 7.32 (dd, J = 8.4, 1.6 Hz, 1H), 3.56 (s, 1H), 2.49 (s, 3H). ¹³C NMR (400 MHz, CDCl₃) δ 150.9, 146.4, 137.2, 135.5, 128.8, 123.6, 121.1, 83.6, 77.0, 21.8. IR (neat) ν_{max} 3185 (br), 2945 (w), 2103 (m), 1604 (m), 1552 (m), 1476 (m), 1401 (m), 1310 (m), 1247 (w), 1116 (s), 1052 (m), 1034 (m), 874 (m), 809 (s), 742 (m), 686 (m), 559 (s).

MS (ESI +ve) m/z 174 ($[M + H]^+$, 100%). HRMS (ESI +ve TOF) calcd for $C_{10}H_8NS^+$ 174.0372, found 174.0377 ($[M + H]^+$).

1-(azidomethyl)-4-fluorobenzene 54.² Following General Procedure B, alkyl bromide **44** (756 mg, 4.00 mmol) and NaN_3 (390 mg, 6.00 mmol) were stirred in anhydrous DMF (20 mL) to afford the azide **54** (500 mg, 83%) as a pale yellow oil after flash chromatography ($CH_2Cl_2/MeOH$ – 90:10). The spectroscopic data was in agreement with that previously reported. TLC ($CH_2Cl_2/MeOH$ – 90:10): R_f = 0.71. 1H NMR (400 MHz, $CDCl_3$) δ 7.32 – 7.28 (m, 2H), 7.10 – 7.06 (m, 2H), 4.32 (s, 2H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 162.8 (d, $^1J_{CF}$ = 245.0 Hz), 131.3 (d, $^4J_{CF}$ = 4.0 Hz), 130.13 (d, $^3J_{CF}$ = 8.0 Hz), 115.9 (d, $^2J_{CF}$ = 22.0 Hz), 54.2. MS (ESI +ve) m/z 152 ($[M + H]^+$, 100%).

1-(azidomethyl)-3-fluorobenzene 55.² Following General Procedure B, alkyl bromide **45** (756 mg, 4.00 mmol) and NaN_3 (390 mg, 6.00 mmol) were stirred in anhydrous DMF (20 mL) to afford the azide **55** (455 mg, 75%) as a pale yellow oil after flash chromatography ($CH_2Cl_2/MeOH$ – 90:10). The spectroscopic data was in agreement with that previously reported. TLC ($CH_2Cl_2/MeOH$ – 90:10): R_f = 0.86. 1H NMR (400 MHz, $CDCl_3$) δ 7.40 – 7.33 (m, 1H), 7.12 – 7.02 (m, 3H), 4.35 (s, 2H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 163.1 (d, $^1J_{CF}$ = 245.0 Hz), 138.0 (d, $^3J_{CF}$ = 7.0 Hz), 130.6, 123.8, 115.2 (d, $^2J_{CF}$ = 41.0 Hz), 115.2, 54.2. MS (ESI +ve) m/z 152 ($[M + H]^+$, 100%).

1-(azidomethyl)-4-(trifluoromethyl)benzene 56.³ Following General Procedure B, alkyl bromide **46** (956 mg, 4.00 mmol) and NaN_3 (390 mg, 6.00 mmol) were stirred in anhydrous DMF (20 mL) to afford the azide **56** (698 mg, 87%) as a pale yellow oil after flash chromatography ($CH_2Cl_2/MeOH$ – 99:1). The spectroscopic data was in agreement with that previously reported. TLC ($CH_2Cl_2/MeOH$ – 99:1): R_f = 0.67. 1H NMR (400 MHz, $CDCl_3$) δ 7.64 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.0 Hz, 2H), 4.43 (s, 2H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 139.6, 130.7 (q, $^2J_{CF}$ = 32.3 Hz), 128.4, 126.0 (q, $^3J_{CF}$ = 3.8 Hz), 125.7 (q, $^1J_{CF}$ = 270.4 Hz), 54.3. MS (ESI +ve) m/z 202 ($[M + H]^+$, 100%).

Azidomethylbenzene 57.² Following General Procedure B, alkyl bromide **47** (684 mg, 4.00 mmol) and NaN_3 (390 mg, 6.00 mmol) were stirred in anhydrous DMF (20 mL) to afford the azide **57** (480 mg, 90%) as a pale yellow oil after flash chromatography ($CH_2Cl_2/MeOH$ – 90:10). The spectroscopic data was in agreement with that previously reported. TLC

(CH₂Cl₂/MeOH – 90:10): R_f = 0.86. ¹H NMR (400 MHz, CDCl₃) δ 7.43 – 7.33 (m, 5H), 4.35 (s, 2H). ¹³C NMR (400 MHz, CDCl₃) δ 135.5, 129.0, 128.4, 128.3, 54.9. MS (ESI +ve) m/z 134 ([M + H]⁺, 100%).

1-(azidomethyl)-4-nitrobenzene 58.³ Following General Procedure B, alkyl bromide **48** (864 mg, 4.00 mmol) and NaN₃ (390 mg, 6.00 mmol) were stirred in anhydrous DMF (20 mL) to afford the azide **58** (550 mg, 77%) as a yellow oil after flash chromatography (CH₂Cl₂/MeOH – 90:10). The spectroscopic data was in agreement with that previously reported. TLC (CH₂Cl₂/MeOH – 90:10): R_f = 0.65. ¹H NMR (400 MHz, CDCl₃) δ 8.20 (d, J = 8.8 Hz, 2H), 7.49 (d, J = 8.8 Hz, 2H), 4.49 (s, 2H). ¹³C NMR (400 MHz, CDCl₃) δ 147.7, 142.8, 128.6, 124.0, 53.7. MS (ESI +ve) m/z 179 ([M + H]⁺, 100%).

4-(azidomethyl)benzonitrile 59.² Following General Procedure B, alkyl bromide **49** (784 mg, 4.00 mmol) and NaN₃ (390 mg, 6.00 mmol) were stirred in anhydrous DMF (20 mL) to afford the azide **59** (490 mg, 77%) as a yellow oil after flash chromatography (CH₂Cl₂/MeOH – 90:10). The spectroscopic data was in agreement with that previously reported. TLC (CH₂Cl₂/MeOH – 90:10): R_f = 0.88. ¹H NMR (400 MHz, CDCl₃) δ 7.67 (d, J = 8.8 Hz, 2H), 7.43 (d, J = 8.8 Hz, 2H), 4.44 (s, 2H). ¹³C NMR (400 MHz, CDCl₃) δ 140.9, 132.7, 128.6, 118.5, 112.3, 54.1. MS (ESI +ve) m/z 159 ([M + H]⁺, 100%).

1-(2-azidoethyl)-4-fluorobenzene 60.² Following General Procedure B, alkyl bromide **50** (812 mg, 4.00 mmol) and NaN₃ (390 mg, 6.00 mmol) were stirred in anhydrous DMF (20 mL) to afford the azide **60** (488 mg, 74%) as a pale yellow oil after flash chromatography (CH₂Cl₂/MeOH – 90:10). The spectroscopic data was in agreement with that previously reported. TLC (CH₂Cl₂/MeOH – 90:10): R_f = 0.69. ¹H NMR (400 MHz, CDCl₃) δ 7.20 – 7.16 (m, 2H), 7.03 – 6.99 (m, 2H), 3.49 (t, J = 6.8 Hz, 2H), 2.87 (t, J = 6.8 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 162.0 (d, ¹J_{CF} = 245.0 Hz), 133.9 (d, ⁴J_{CF} = 4.0 Hz), 130.36 (d, ³J_{CF} = 8.0 Hz), 115.6 (d, ²J_{CF} = 22.0 Hz), 52.6, 34.7. MS (ESI +ve) m/z 166 ([M + H]⁺, 100%).

1-(2-azidoethyl)-4-(trifluoromethyl)benzene 61.⁴ Following General Procedure B, alkyl bromide **51** (1.01 g, 4.00 mmol) and NaN₃ (390 mg, 6.00 mmol) were stirred in anhydrous DMF (20 mL) to afford the azide **61** (711 mg, 83%) as a pale yellow oil after flash chromatography (CH₂Cl₂/MeOH – 90:10). The spectroscopic data was in agreement with that previously reported. TLC (CH₂Cl₂/MeOH – 90:10): R_f = 0.77. ¹H NMR (500 MHz, CDCl₃) δ

7.59 (d, $J = 6.4$ Hz, 2H), 7.34 (d, $J = 6.4$ Hz, 2H), 3.55 (t, $J = 5.6$ Hz, 2H), 2.95 (t, $J = 5.6$ Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 142.3, 129.4 (q, $^2J_{\text{CF}} = 32.3$ Hz), 129.3, 125.7 (q, $^3J_{\text{CF}} = 3.8$ Hz), 125.6 (q, $^1J_{\text{CF}} = 270.4$ Hz), 52.1, 35.3. MS (ESI +ve) m/z 216 ([M + H]⁺, 100%).

4-(2-azidoethyl)phenol 62.² Following General Procedure B, alkyl bromide **52** (805 mg, 4.00 mmol) and NaN_3 (390 mg, 6.00 mmol) were stirred in anhydrous DMF (20 mL) to afford the azide **62** (511 mg, 78%) as a colourless oil after flash chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH} - 90:10$). The spectroscopic data was in agreement with that previously reported. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH} - 90:10$): $R_f = 0.60$. ^1H NMR (400 MHz, CDCl_3) δ 7.09 (d, $J = 8.8$ Hz, 2H), 6.79 (d, $J = 8.8$ Hz, 2H), 5.15 (s, 1H), 3.46 (t, $J = 7.2$ Hz, 2H), 2.83 (t, $J = 7.2$ Hz, 2H). ^{13}C NMR (400 MHz, CDCl_3) δ 154.5, 130.3, 130.1, 115.6, 52.8, 34.6. MS (ESI +ve) m/z 164 ([M + H]⁺, 100%).

1-(2-azidoethyl)-4-nitrobenzene 63.⁵ Following General Procedure B, alkyl bromide **53** (920 mg, 4.00 mmol) and NaN_3 (390 mg, 6.00 mmol) were stirred in anhydrous DMF (20 mL) to afford the azide **63** (601 mg, 78%) as a yellow oil after flash chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH} - 95:5$). The spectroscopic data was in agreement with that previously reported. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH} - 95:5$): $R_f = 0.63$. ^1H NMR (400 MHz, CDCl_3) δ 8.17 (d, $J = 7.2$ Hz, 2H), 7.40 (d, $J = 7.2$ Hz, 2H), 3.58 (t, $J = 5.2$ Hz, 2H), 2.99 (t, $J = 5.2$ Hz, 2H). ^{13}C NMR (400 MHz, CDCl_3) δ 147.1, 145.9, 129.8, 123.9, 51.8, 35.3. MS (ESI +ve) m/z 193 ([M + H]⁺, 100%).

2-(1-(4-fluorobenzyl)-1*H*-1,2,3-triazol-4-yl)-6-methoxybenzo[*d*]thiazole 64. Following General Procedure A₁, alkyne **25** (40 mg, 0.21 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **54** (64 mg, 0.42 mmol) were stirred in *t*-BuOH/ H_2O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **64** (55 mg, 77%) as a pale yellow solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH} - 98:2$). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH} - 98:2$): $R_f = 0.55$. Mp 175 °C. ^1H NMR (500 MHz, DMSO) δ 8.95 (s, 1H), 7.90 (d, $J = 9.0$ Hz, 1H), 7.73 (d, $J = 2.4$ Hz, 1H), 7.51 – 7.47 (m, 2H), 7.26 – 7.22 (m, 2H), 7.15 (dd, $J = 9.0, 2.4$ Hz, 1H), 5.84 (s, 2H), 3.85 (s, 3H). ^{13}C NMR (125 MHz, DMSO) δ 162.0 (d, $^1J_{\text{CF}} = 243.3$ Hz), 157.6, 156.3, 147.6, 142.3, 135.4, 131.8 (d, $^4J_{\text{CF}} = 2.8$ Hz), 130.5 (d, $^3J_{\text{CF}} = 8.6$ Hz), 123.4, 123.1, 115.8 (d, $^2J_{\text{CF}} = 44.4$ Hz), 115.8, 104.9, 55.7, 52.5. IR (neat) ν_{max} 3200 (w), 2831 (w), 2230 (w), 1605 (m), 1580 (w), 1557 (m), 1508 (m), 1489 (m), 1465 (m), 1435 (s), 1259 (s), 1219 (m), 1184 (m), 1157 (m), 1128 (s), 948 (m), 887 (s) cm^{-1} . MS (ESI +ve) m/z

341 ([M + H]⁺, 100%); (ESI -ve) *m/z* 339 ([M - H]⁻, 100%). HRMS (ESI +ve TOF) calcd for C₁₇H₁₄FN₄OS⁺ 341.0867, found 341.0872 ([M + H]⁺).

2-(1-(4-fluorophenethyl)-1*H*-1,2,3-triazol-4-yl)-6-methoxybenzo[*d*]thiazole 65. Following General Procedure A₁, alkyne **25** (40 mg, 0.21 mmol), CuSO₄.5H₂O (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **60** (69 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **65** (51 mg, 69%) as a pale yellow solid after preparative TLC plate chromatography (CH₂Cl₂/MeOH – 98:2). TLC (CH₂Cl₂/MeOH – 98:2): R_f = 0.57. Mp 149 °C. ¹H NMR (400 MHz, DMSO) δ 8.80 (s, 1H), 7.89 (d, *J* = 9.0 Hz, 1H), 7.72 (d, *J* = 2.4 Hz, 1H), 7.28 – 7.24 (m, 2H), 7.14 – 7.10 (m, 2H), 7.09 (dd, *J* = 9.0, 2.4 Hz, 1H), 4.73 (t, *J* = 7.2 Hz, 2H), 3.85 (s, 3H), 3.25 (t, *J* = 7.2 Hz, 2H). ¹³C NMR (100 MHz, DMSO) δ 161.1 (d, ¹J_{CF} = 240.7 Hz), 157.5, 156.5, 147.6, 141.9, 135.3, 133.6 (d, ⁴J_{CF} = 3.1 Hz), 130.6 (d, ³J_{CF} = 8.0 Hz), 123.3, 123.1, 115.9, 115.2 (d, ²J_{CF} = 21.0 Hz), 104.9, 55.7, 50.9, 34.5. IR (neat) ν_{max} 3107 (w), 2841 (w), 2229 (w), 1610 (m), 1582 (m), 1554 (m), 1489 (m), 1466 (m), 1437 (s), 1325 (m), 1278 (s), 1215 (s), 1161 (m), 1116 (m), 943 (m), 877 (s) cm⁻¹. MS (ESI +ve) *m/z* 355 ([M + H]⁺, 100%). HRMS (ESI +ve TOF) calcd for C₁₈H₁₆FN₄OS⁺ 355.1023, found 355.1029 ([M + H]⁺).

2-(1-(3-fluorobenzyl)-1*H*-1,2,3-triazol-4-yl)-6-methoxybenzo[*d*]thiazole 66. Following General Procedure A₁, alkyne **25** (40 mg, 0.21 mmol), CuSO₄.5H₂O (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **55** (63 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **66** (60 mg, 84%) as a pale yellow solid after preparative TLC plate chromatography (CH₂Cl₂/MeOH – 98:2). TLC (CH₂Cl₂/MeOH – 98:2): R_f = 0.50. Mp 170 °C. ¹H NMR (400 MHz, DMSO) δ 8.98 (s, 1H), 7.90 (d, *J* = 9.0 Hz, 1H), 7.73 (d, *J* = 2.4 Hz), 7.46 – 7.42 (m, 1H), 7.30 – 7.18 (m, 3H), 7.14 (dd, *J* = 9.0, 2.4 Hz, 1H), 4.74 (s, 2H), 3.85 (s, 3H). ¹³C NMR (100 MHz, DMSO) δ 162.2 (d, ¹J_{CF} = 243.0 Hz), 157.6, 156.6, 147.6, 142.3, 138.2 (d, ³J_{CF} = 7.8 Hz), 135.4, 131.0, 130.9, 124.2, 123.7, 116.0, 115.1 (d, ²J_{CF} = 40.4 Hz), 115.1, 104.9, 55.7, 52.6. IR (neat) ν_{max} 3121 (w), 2840 (w), 2220 (w), 1608 (m), 1582 (m), 1553 (m), 1490 (m), 1460 (m), 1431 (s), 1319 (m), 1268 (s), 1211 (s), 1159 (m), 1130 (m), 943 (m), 878 (s) cm⁻¹. MS (ESI +ve) *m/z* 341 ([M + H]⁺, 100%); (ESI -ve) *m/z* 339 ([M - H]⁻, 100%). HRMS (ESI +ve TOF) calcd for C₁₇H₁₄FN₄OS⁺ 341.0867, found 341.0872 ([M + H]⁺).

6-methoxy-2-(1-(4-(trifluoromethyl)benzyl)-1*H*-1,2,3-triazol-4-yl)benzo[*d*]thiazole 67.

Following General Procedure A₁, alkyne **25** (40 mg, 0.21 mmol), CuSO₄.5H₂O (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **56** (84 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **67** (61 mg, 74%) as a pale yellow solid after preparative TLC plate chromatography (CH₂Cl₂/MeOH – 98:2). TLC (CH₂Cl₂/MeOH – 98:2): R_f = 0.66. Mp 174 °C. ¹H NMR (400 MHz, DMSO) δ 9.01 (s, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.78 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 2.4 Hz, 1H), 7.60 (d, J = 8.0 Hz, 2H), 7.14 (dd, J = 8.8, 2.4 Hz, 1H), 5.85 (s, 2H), 3.85 (s, 3H). ¹³C NMR (100 MHz, DMSO) δ 158.1, 156.7, 148.1, 142.9, 140.7, 135.9, 129.3, 129.3 (q, ²J_{CF} = 31.8 Hz), 126.3 (q, ³J_{CF} = 3.8 Hz), 125.0 (q, ¹J_{CF} = 270.4 Hz), 124.3, 123.6, 116.5, 105.4, 56.2, 53.1. IR (neat) ν_{max} 3142 (w), 2841 (w), 2215 (w), 1608 (m), 1579 (m), 1553 (m), 1491 (m), 1459 (m), 1436 (s), 1324 (m), 1272 (s), 1215 (s), 1160 (m), 1120 (m), 948 (m), 874 (s) cm⁻¹. MS (ESI +ve) m/z 391 ([M + H]⁺, 100%); (ESI -ve) m/z 389 ([M – H]⁻, 100%). HRMS (ESI +ve TOF) calcd for C₁₈H₁₄F₃N₄OS⁺ 391.0835, found 391.0840 ([M + H]⁺).

6-methoxy-2-(1-(4-(trifluoromethyl)phenethyl)-1*H*-1,2,3-triazol-4-yl)benzo[*d*]thiazole 68.

Following General Procedure A₁, alkyne **25** (40 mg, 0.21 mmol), CuSO₄.5H₂O (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **61** (90 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **68** (60 mg, 71%) as a pale yellow solid after preparative TLC plate chromatography (CH₂Cl₂/MeOH – 98:2). TLC (CH₂Cl₂/MeOH – 98:2): R_f = 0.71. Mp 167 °C. ¹H NMR (500 MHz, DMSO) δ 8.86 (s, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.72 (d, J = 2.4 Hz, 1H), 7.65 (d, J = 8.0 Hz, 2H), 7.47 (d, J = 8.0 Hz, 2H), 7.13 (dd, J = 8.8, 2.4 Hz, 1H), 4.80 (t, J = 5.6 Hz, 2H), 3.85 (s, 3H), 3.37 (t, J = 5.6 Hz, 2H). ¹³C NMR (125 MHz, DMSO) δ 157.6, 156.4, 147.6, 142.4, 142.0, 135.3, 129.6, 127.4 (q, ²J_{CF} = 31.8 Hz), 125.3 (q, ³J_{CF} = 3.8 Hz), 124.6 (q, ¹J_{CF} = 270.4 Hz), 123.3, 123.1, 115.9, 104.9, 55.7, 50.4, 35.0. IR (neat) ν_{max} 3107 (w), 2922 (w), 2229 (w), 1606 (m), 1570 (m), 1516 (s), 1484 (m), 1452 (m), 1344 (s), 1312 (m), 1228 (m), 1178 (m), 1130 (m), 1106 (m), 948 (s), 882 (s) cm⁻¹. MS (ESI +ve) m/z 405 ([M + H]⁺, 100%); (ESI -ve) m/z 403 ([M – H]⁻, 100%). HRMS (ESI +ve TOF) calcd for C₁₉H₁₆F₃N₄OS⁺ 405.0991, found 405.0997 ([M + H]⁺).

2-(1-benzyl-1*H*-1,2,3-triazol-4-yl)-6-methoxybenzo[*d*]thiazole 69. Following General Procedure A₁, alkyne **25** (40 mg, 0.21 mmol), CuSO₄.5H₂O (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **57** (56 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **69** (58 mg, 86%) as a pale yellow

solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 98:2). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 98:2): $R_f = 0.67$. Mp 162 °C. ^1H NMR (500 MHz, DMSO) δ 8.95 (s, 1H), 7.90 (d, $J = 9.0$ Hz, 1H), 7.73 (d, $J = 3.0$ Hz, 1H), 7.34 – 7.12 (m, 5H), 7.13 (dd, $J = 9.0, 3.0$ Hz, 1H), 5.71 (s, 2H), 3.85 (s, 3H). ^{13}C NMR (500 MHz, DMSO) δ 157.6, 156.3, 147.6, 142.3, 135.6, 135.4, 128.9, 128.3, 128.1, 123.5, 123.1, 116.0, 104.9, 55.7, 53.3. IR (neat) ν_{\max} 3140 (w), 2980 (w), 2241 (w), 1607 (s), 1576 (m), 1556 (m), 1489 (m), 1465 (m), 1430 (m), 1322 (s), 1255 (s), 1222 (m), 1180 (s), 1040 (m), 1026 (m), 945 (m), 887 (s) cm^{-1} . MS (ESI +ve) m/z 323 ([M + H]⁺, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{17}\text{H}_{15}\text{N}_4\text{OS}^+$ 323.0961, found 323.0967 ([M + H]⁺).

4-(2-(4-(6-methoxybenzo[d]thiazol-2-yl)-1*H*-1,2,3-triazol-1-yl)ethyl)phenol 70. Following General Procedure A₂, alkyne **25** (40 mg, 0.21 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **62** (69 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **70** (52 mg, 70%) as a white solid after sequential trituration with CH_2Cl_2 , MeCN, and hot MeOH. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 90:10): $R_f = 0.05$. Mp 160 °C (decomp). ^1H NMR (400 MHz, DMSO) δ 9.25 (s, 1H), 8.74 (s, 1H), 7.89 (d, $J = 8.8$ Hz, 1H), 7.72 (d, $J = 2.4$ Hz, 1H), 7.13 (dd, $J = 8.8, 2.4$ Hz), 7.00 (d, $J = 8.4$ Hz, 2H), 6.66 (d, $J = 8.4$ Hz, 2H), 4.66 (t, $J = 7.2$ Hz, 2H), 3.85 (s, 3H), 3.12 (t, $J = 7.2$ Hz, 2H). ^{13}C NMR (400 MHz, DMSO) δ 157.5, 156.5, 156.0, 147.6, 141.8, 135.3, 129.6, 127.3, 123.2, 123.1, 115.9, 115.2, 104.9, 55.7, 51.3, 34.7. IR (neat) ν_{\max} 3133 (w), 2981 (w), 2092 (br), 1610 (m), 1555 (m), 1516 (m), 1489 (m), 1463 (m), 1378 (w), 1356 (w), 1320 (s), 1238 (s), 1216 (m), 1131 (m), 1102 (m), 950 (m), 864 (s) cm^{-1} . MS (ESI +ve) m/z 353 ([M + H]⁺, 100%); (ESI -ve) m/z 351 ([M – H]⁻, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{18}\text{H}_{17}\text{N}_4\text{O}_2\text{S}^+$ 353.1067, found 353.1072 ([M + H]⁺).

6-methoxy-2-(1-(4-nitrobenzyl)-1*H*-1,2,3-triazol-4-yl)benzo[d]thiazole 71. Following General Procedure A₂, alkyne **25** (40 mg, 0.21 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **58** (75 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **71** (61 mg, 79%) as a pale yellow solid after sequential trituration with CH_2Cl_2 , MeCN, and hot MeOH. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 90:10): $R_f = 0.24$. Mp 162 °C (decomp). ^1H NMR (400 MHz, DMSO) δ 8.85 (s, 1H), 8.23 (d, $J = 8.4$ Hz, 2H), 7.89 (d, $J = 8.8$ Hz, 1H), 7.66 (d, $J = 2.4$ Hz, 1H), 7.65 (d, $J = 8.4$ Hz, 2H), 7.14 (dd, $J = 8.8, 2.4$ Hz, 1H), 5.88 (s, 2H), 3.89 (s, 3H). ^{13}C NMR (500 MHz, DMSO) δ 157.6, 156.2, 147.6, 147.3, 142.9, 142.4, 135.4, 129.2, 124.0, 123.2, 122.3, 116.0,

104.9, 55.7, 52.4. IR (neat) ν_{max} 3121 (w), 2900 (w), 2089 (w), 1610 (m), 1555 (s), 1516 (s), 1489 (m), 1432 (m), 1378 (s), 1356 (m), 1320 (m), 1272 (s), 1215 (s), 1174 (s), 1044 (m), 1027 (m), 949 (m), 818 (m) cm^{-1} . MS (ESI +ve) m/z 368 ($[\text{M} + \text{H}]^+$, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{17}\text{H}_{14}\text{N}_5\text{O}_3\text{S}^+$ 368.0812, found 368.0817 ($[\text{M} + \text{H}]^+$).

6-methoxy-2-(1-(4-nitrophenethyl)-1*H*-1,2,3-triazol-4-yl)benzo[*d*]thiazole 72. Following General Procedure A₂, alkyne **25** (40 mg, 0.21 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **63** (81 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **72** (60 mg, 75%) as a pale yellow solid after sequential trituration with CH_2Cl_2 , MeCN, and hot MeOH. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 90:10): R_f = 0.22. Mp 172 °C (decomp). ¹H NMR (400 MHz, DMSO) δ 8.85 (s, 1H), 8.15 (d, J = 8.4 Hz, 2H), 7.89 (d, J = 8.8 Hz, 1H), 7.72 (d, J = 2.8 Hz, 1H), 7.53 (d, J = 8.4 Hz, 2H), 7.13 (dd, J = 8.8, 2.8 Hz, 1H), 4.83 (t, J = 7.2 Hz, 2H), 3.85 (s, 3H), 3.43 (t, J = 7.2 Hz, 2H). ¹³C NMR (400 MHz, DMSO) δ 157.6, 156.4, 147.6, 146.4, 145.7, 142.0, 135.3, 130.1, 123.5, 123.3, 123.1, 115.9, 104.9, 55.7, 50.2, 34.9. IR (neat) ν_{max} 3131 (w), 2924 (w), 1604 (m), 1558 (s), 1512 (s), 1490 (m), 1438 (m), 1374 (s), 1342 (m), 1315 (m), 1259 (s), 1226 (s), 1178 (s), 1040 (m), 1021 (m), 945 (m), 827 (m) cm^{-1} . MS (ESI +ve) m/z 382 ($[\text{M} + \text{H}]^+$, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{18}\text{H}_{16}\text{N}_5\text{O}_3\text{S}^+$ 382.0968, found 382.0974 ($[\text{M} + \text{H}]^+$).

4-((4-(6-methoxybenzo[*d*]thiazol-2-yl)-1*H*-1,2,3-triazol-1-yl)methyl)benzonitrile 73. Following General Procedure A₁, alkyne **25** (40 mg, 0.21 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **59** (66 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **73** (53 mg, 73%) as a pale yellow solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 90:10). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 90:10): R_f = 0.25. Mp 178 °C (decomp). ¹H NMR (400 MHz, DMSO) δ 9.00 (s, 1H), 7.92 (d, J = 8.8 Hz, 1H), 7.87 (d, J = 8.4 Hz, 2H), 7.73 (d, J = 2.4 Hz, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.15 (dd, J = 8.8, 2.4 Hz, 1H), 5.84 (s, 2H), 3.85 (s, 3H). ¹³C NMR (400 MHz, DMSO) δ 157.6, 156.2, 147.6, 142.4, 140.9, 135.4, 132.8, 128.8, 123.9, 123.2, 118.5, 116.0, 111.1, 104.9, 55.8, 52.6. IR (neat) ν_{max} 3143 (w), 2231 (w), 1607 (s), 1580 (m), 1509 (m), 1490 (m), 1459 (m), 1375 (w), 1253 (s), 1228 (s), 1038 (m), 1023 (m), 950 (m), 874 (s), 824 (m) cm^{-1} . MS (ESI +ve) m/z 348 ($[\text{M} + \text{H}]^+$, 100%), 370 ($[\text{M} + \text{Na}]^+$, 20%); (ESI -ve) m/z 346 ($[\text{M} - \text{H}]^-$, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{18}\text{H}_{14}\text{N}_5\text{OS}^+$ 348.0914, found 348.0919 ($[\text{M} + \text{H}]^+$).

2-(1-(4-fluorobenzyl)-1*H*-1,2,3-triazol-4-yl)-6-methylbenzo[*d*]thiazole 74. Following General Procedure A₁, alkyne **43** (36 mg, 0.21 mmol), CuSO₄.5H₂O (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **54** (63 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **74** (53 mg, 78%) as a pale yellow solid after preparative TLC plate chromatography (CH₂Cl₂/MeOH – 98:2). TLC (CH₂Cl₂/MeOH – 98:2): R_f = 0.84. Mp 184 °C. ¹H NMR (400 MHz, DMSO) δ 8.99 (s, 1H), 7.93 (br s, 1H), 7.89 (d, J = 9.0 Hz, 1H), 7.51 – 7.47 (m, 2H), 7.35 (dd, J = 9.0, 2.4 Hz, 1H), 7.27 – 7.22 (m, 2H), 5.71 (s, 2H), 2.45 (s, 3H). ¹³C NMR (100 MHz, DMSO) δ 162.0 (d, ¹J_{CF} = 243.3 Hz), 157.8, 151.3, 142.3, 135.4, 134.0, 131.8 (d, ⁴J_{CF} = 2.8 Hz), 130.5 (d, ³J_{CF} = 8.6 Hz), 128.1, 123.77, 122.2, 121.9, 115.7 (d, ²J_{CF} = 44.4 Hz), 52.5, 21.0. IR (neat) ν_{max} 3123 (w), 2912 (w), 1605 (m), 1551 (m), 1508 (m), 1486 (m), 1461 (m), 1435 (s), 1353 (m), 1333 (m), 1221 (s), 1158 (m), 1128 (m), 1117 (s), 1090 (m), 950 (m), 818 (s) cm⁻¹. MS (ESI +ve) m/z 325 ([M + H]⁺, 100%). HRMS (ESI +ve TOF) calcd for C₁₇H₁₄FN₄S⁺ 325.0918, found 325.0923 ([M + H]⁺).

2-(1-(4-fluorophenethyl)-1*H*-1,2,3-triazol-4-yl)-6-methylbenzo[*d*]thiazole 75. Following General Procedure A₁, alkyne **43** (36 mg, 0.21 mmol), CuSO₄.5H₂O (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **60** (69 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **75** (49 mg, 69%) as a pale yellow solid after preparative TLC plate chromatography (CH₂Cl₂/MeOH – 95:5). TLC (CH₂Cl₂/MeOH – 95:5): R_f = 0.79. Mp 178 °C. ¹H NMR (400 MHz, DMSO) δ 8.83 (s, 1H), 7.92 (br s, 1H), 7.89 (d, J = 9.0 Hz, 1H), 7.35 (dd, J = 9.0, 2.4 Hz, 1H), 7.28 – 7.24 (m, 2H), 7.13 – 7.08 (m, 2H), 4.73 (t, J = 7.2 Hz, 2H), 3.25 (t, J = 7.2 Hz, 2H), 2.45 (s, 3H). ¹³C NMR (100 MHz, DMSO) δ 161.1 (d, ¹J_{CF} = 240.7 Hz), 158.0, 151.3, 142.0, 135.3, 133.9, 133.5 (d, ⁴J_{CF} = 3.1 Hz), 130.6 (d, ³J_{CF} = 8.0 Hz), 128.0, 123.6, 122.1, 121.9, 115.2 (d, ²J_{CF} = 21.0 Hz), 50.9, 34.5, 21.0. IR (neat) ν_{max} 3129 (w), 2950 (w), 1609 (m), 1578 (m), 1516 (m), 1487 (m), 1450 (m), 1431 (s), 1382 (m), 1357 (m), 1269 (m), 1236 (m), 1131 (m), 1055 (m), 1024 (m), 973 (m), 809 (s) cm⁻¹. MS (ESI +ve) m/z 339 ([M + H]⁺, 100%). HRMS (ESI +ve TOF) calcd for C₁₈H₁₆FN₄S⁺ 339.1074, found 339.1080 ([M + H]⁺).

6-methyl-2-(1-(4-(trifluoromethyl)benzyl)-1*H*-1,2,3-triazol-4-yl)benzo[*d*]thiazole 76. Following General Procedure A₁, alkyne **43** (36 mg, 0.21 mmol), CuSO₄.5H₂O (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **56** (84 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **76** (57 mg, 73%) as a

pale yellow solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5): $R_f = 0.87$. Mp 175 °C. ^1H NMR (400 MHz, DMSO) δ 9.05 (s, 1H), 7.94 (br s, 1H), 7.91 (d, $J = 9.0$ Hz, 1H), 7.77 (d, $J = 8.4$ Hz, 2H), 7.60 (d, $J = 8.4$ Hz, 2H), 7.36 (dd, $J = 8.4, 1.2$ Hz), 5.85 (s, 2H), 2.45 (s, 3H). ^{13}C NMR (100 MHz, DMSO) δ 156.8, 151.33, 142.34, 140.2, 135.4, 134.0, 128.9 (q, $^2J_{\text{CF}} = 31.8$ Hz), 128.8, 128.1, 125.7 (q, $^3J_{\text{CF}} = 3.8$ Hz), 124.4 (q, $^1J_{\text{CF}} = 270.4$ Hz), 124.2, 122.2, 122.0, 52.7, 21.0. IR (neat) ν_{max} 3138 (w), 2930 (w), 1609 (m), 1556 (m), 1507 (m), 1488 (m), 1454 (m), 1436 (s), 1323 (m), 1228 (s), 1174 (m), 1161 (m), 1119 (s), 1106 (m), 1066 (m), 949 (m), 808 (s) cm⁻¹. MS (ESI +ve) m/z 375 ([M + H]⁺, 100%); (ESI -ve) m/z 373 ([M – H]⁻, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{18}\text{H}_{14}\text{F}_3\text{N}_4\text{S}^+$ 375.0886, found 375.0891 ([M + H]⁺).

4-(2-(4-(6-methylbenzo[d]thiazol-2-yl)-1*H*-1,2,3-triazol-1-yl)ethyl)phenol 77. Following General Procedure A₂, alkyne **43** (36 mg, 0.21 mmol), CuSO₄.5H₂O (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **62** (69 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **77** (57 mg, 81%) as a pale yellow solid after sequential trituration with CH₂Cl₂, MeCN, and hot MeOH. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 90:10): $R_f = 0.41$. Mp 150 °C (decomp). ^1H NMR (400 MHz, DMSO) δ 9.24 (s, 1H), 8.78 (s, 1H), 7.93 (br s, 1H), 7.89 (d, $J = 8.4$ Hz, 1H), 7.36 (dd, $J = 8.4, 2.0$ Hz, 1H), 7.00 (d, $J = 8.0$ Hz, 2H), 6.65 (d, $J = 8.0$ Hz, 2H), 4.66 (t, $J = 7.2$ Hz, 2H), 3.13 (t, $J = 7.2$ Hz, 2H), 2.49 (s, 3H). ^{13}C NMR (400 MHz, DMSO) δ 158.0, 156.0, 151.3, 141.8, 135.3, 133.9, 129.6, 128.0, 127.3, 123.6, 122.1, 121.9, 115.2, 51.3, 34.7, 21.0. IR (neat) ν_{max} 3128 (br), 2950 (w), 1609 (m), 1589 (m), 1516 (m), 1486 (m), 1449 (m), 1381 (w), 1357 (w), 1314 (s), 1296 (m), 1268 (m), 1237 (s), 1197 (m), 1175 (m), 1131 (m), 973 (m), 872 (s). MS (ESI +ve) m/z 337 ([M + H]⁺, 100%); (ESI -ve) m/z 335 ([M – H]⁻, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{18}\text{H}_{17}\text{N}_4\text{OS}^+$ 337.1118, found 337.1123 ([M + H]⁺).

6-methyl-2-(1-(4-nitrobenzyl)-1*H*-1,2,3-triazol-4-yl)benzo[d]thiazole 78. Following General Procedure A₂, alkyne **43** (36 mg, 0.21 mmol), CuSO₄.5H₂O (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **63** (75 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **78** (55 mg, 75%) as a pale yellow solid after sequential trituration with CH₂Cl₂, MeCN, and hot MeOH. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 90:10): $R_f = 0.44$. Mp 152 °C (decomp). ^1H NMR (500 MHz, DMSO) δ 9.06 (s, 1H), 8.25 (d, $J = 9.0$ Hz, 2H), 7.93 (br s, 1H), 7.90 (d, $J = 8.5$ Hz, 1H), 7.63 (d, $J = 9.0$ Hz, 2H), 7.36 (dd, $J = 8.5, 2.0$ Hz, 1H), 5.91 (s, 2H), 2.45 (s, 3H). ^{13}C NMR (500 MHz, DMSO) δ

157.7, 151.3, 147.4, 142.9, 142.4, 135.4, 134.0, 129.3, 128.1, 124.3, 124.0, 122.2, 122.0, 52.4, 21.1. IR (neat) ν_{max} 3108 (w), 2900 (w), 2106 (w), 1607 (m), 1515 (s), 1484 (m), 1451 (m), 1345 (s), 1312 (m), 1269 (s), 1228 (s), 1174 (m), 1131 (m), 1039 (m), 1016 (m), 947 (m), 815 (s), 775 (s). MS (ESI +ve) m/z 352 ([M + H]⁺, 100%). HRMS (ESI +ve TOF) calcd for C₁₇H₁₄N₅O₂S⁺ 352.0863, found 352.0868 ([M + H]⁺).

2-azidoethan-1-ol 84.⁶ Following General Procedure B, alkyl bromide **79** (500 mg, 4.00 mmol) and NaN₃ (390 mg, 6.00 mmol) were stirred in anhydrous DMF (20 mL) to afford the azide **84** (315 mg, 90%) as a pale yellow oil which was used for the next reaction without further purification. The spectroscopic data was in agreement with that previously reported. TLC (CH₂Cl₂/MeOH – 99:1): R_f = 0.41. ¹H NMR (400 MHz, CDCl₃) δ 3.77 (t, *J* = 5.2 Hz, 2H), 3.44 (t, *J* = 5.2 Hz, 2H) 2.14 (br s, 1H). ¹³C NMR (400 MHz, CDCl₃) δ 61.6, 53.7. MS (ESI +ve) m/z 88 ([M + H]⁺, 100%).

3-azidopropan-1-ol 85.⁷ Following General Procedure B, alkyl bromide **80** (556 mg, 4.00 mmol) and NaN₃ (390 mg, 6.00 mmol) were stirred in anhydrous DMF (20 mL) to afford the azide **85** (390 mg, 96%) as a pale yellow oil which was used for the next reaction without further purification. The spectroscopic data was in agreement with that previously reported. TLC (CH₂Cl₂/MeOH – 99:1): R_f = 0.44. ¹H NMR (400 MHz, CDCl₃) δ 3.70 (t, *J* = 6.0 Hz, 2H), 3.41 (t, *J* = 6.0 Hz, 2H) 2.42 (br s, 1H), 1.79 (quint, *J* = 6.0 Hz, 2H). ¹³C NMR (400 MHz, CDCl₃) δ 59.7, 48.5, 31.5. MS (ESI +ve) m/z 102 ([M + H]⁺, 100%).

7-azidoheptan-1-ol 86.⁸ Following General Procedure B, alkyl bromide **81** (780 mg, 4.00 mmol) and NaN₃ (390 mg, 6.00 mmol) were stirred in anhydrous DMF (20 mL) to afford the azide **86** (588 mg, 94%) as a pale yellow oil which was used for the next reaction without further purification. The spectroscopic data was in agreement with that previously reported. TLC (CH₂Cl₂/MeOH – 95:5): R_f = 0.40. ¹H NMR (400 MHz, CDCl₃) δ 3.59 (t, *J* = 6.8 Hz, 2H), 3.35 (t, *J* = 6.8 Hz, 1H) 3.22 (t, *J* = 6.8 Hz, 2H), 1.58 – 1.49 (m, 4H), 1.36 – 1.26 (m, 6H). ¹³C NMR (400 MHz, CDCl₃) δ 62.8, 51.5, 32.8, 29.0, 28.8, 26.7, 25.7. MS (ESI +ve) m/z 158 ([M + H]⁺, 100%).

8-azidoctan-1-ol 87.⁹ Following General Procedure B, alkyl bromide **82** (836 mg, 4.00 mmol) and NaN₃ (390 mg, 6.00 mmol) were stirred in anhydrous DMF (20 mL) to afford the azide **87** (622 mg, 91%) as a pale yellow oil which was used for the next reaction without

further purification. The spectroscopic data was in agreement with that previously reported. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5): R_f = 0.38. ^1H NMR (400 MHz, CDCl_3) δ 3.60 (t, J = 6.4 Hz, 2H), 3.23 (t, J = 6.8 Hz, 2H), 1.75 (br s, 1H), 1.61 – 1.50 (m, 4H), 1.36 – 1.30 (m, 8H). ^{13}C NMR (400 MHz, CDCl_3) δ 63.0, 51.5, 32.8, 29.3, 29.2, 28.9, 26.7, 25.7. MS (ESI +ve) m/z 172 ([M + H]⁺, 100%).

2-(2-azidoethoxy)ethan-1-ol 88.¹⁰ **Following General Procedure B**, alkyl bromide **83** (676 mg, 4.00 mmol) and NaN_3 (390 mg, 6.00 mmol) were stirred in anhydrous DMF (20 mL) to afford the azide **88** (499 mg, 95%) as a pale yellow oil which was used for the next reaction without further purification. The spectroscopic data was in agreement with that previously reported. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5): R_f = 0.41. ^1H NMR (400 MHz, CDCl_3) δ 3.78 – 3.74 (m, 2H), 3.71 – 3.69 (m, 2H) 3.63 – 3.61 (m, 2H), 3.43 – 3.41 (m, 2H), 2.38 (t, J = 6.0 Hz, 1H). ^{13}C NMR (400 MHz, CDCl_3) δ 72.5, 70.1, 61.8, 50.8. MS (ESI +ve) m/z 132 ([M + H]⁺, 100%).

2-(4-(6-methoxybenzo[d]thiazol-2-yl)-1*H*-1,2,3-triazol-1-yl)ethan-1-ol 89. **Following General Procedure A₁**, alkyne **25** (40 mg, 0.21 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **84** (37 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **89** (49 mg, 84%) as a pale yellow solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5): R_f = 0.74. Mp 178 °C (decomp). ^1H NMR (400 MHz, DMSO) δ 8.78 (s, 1H), 7.91 (d, J = 8.8 Hz, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.14 (dd, J = 8.8, 2.4 Hz, 1H), 5.09 (t, J = 5.2 Hz, 1H), 4.52 (t, J = 5.6 Hz, 2H), 3.86 (s, 3H), 3.85 (dt, J = 5.6, 5.2 Hz, 2H). ^{13}C NMR (400 MHz, CDCl_3) δ 157.5, 156.6, 147.6, 141.8, 135.3, 123.7, 123.1, 115.9, 105.0, 59.6, 55.7, 52.7. IR (neat) ν_{max} 3216 (br), 2922 (w), 2853 (w), 1608 (m), 1560 (w), 1434 (m), 1420 (m), 1258 (s), 1229 (s), 1081 (s), 1069 (m), 959 (m), 834 (s), 715 (w), 676 (m) cm^{-1} . MS (ESI +ve) m/z 277 ([M + H]⁺, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{12}\text{H}_{13}\text{N}_4\text{O}_2\text{S}^+$ 277.0754, found 277.0754 ([M + H]⁺).

3-(4-(6-methoxybenzo[d]thiazol-2-yl)-1*H*-1,2,3-triazol-1-yl)propan-1-ol 90.¹¹ **Following General Procedure A₁**, alkyne **25** (40 mg, 0.21 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **85** (43 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **90** (50 mg, 82%) as a pale yellow solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5). The spectroscopic data was in agreement with that previously reported. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ –

95:5): R_f = 0.77. Mp 131 °C. ^1H NMR (400 MHz, DMSO) δ 8.85 (s, 1H), 7.91 (d, J = 8.8 Hz, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.15 (dd, J = 8.8, 2.4 Hz, 1H), 4.71 (t, J = 5.2 Hz, 1H), 4.53 (t, J = 6.8 Hz, 2H), 3.85 (s, 3H), 3.44 (dt, J = 6.8, 5.2 Hz, 2H), 2.05 (quint, J = 6.8 Hz, 2H). ^{13}C NMR (400 MHz, DMSO) δ 157.5, 156.6, 147.6, 142.0, 135.4, 123.4, 123.1, 115.9, 105.0, 57.6, 55.7, 47.3, 32.7. IR (neat) ν_{max} 3306 (br), 2926 (w), 2834 (w), 1604 (m), 1556 (w), 1434 (m), 1411 (m), 1266 (s), 1223 (s), 1066 (s), 1040 (s), 950 (s), 838 (s), 711 (w), 679 (m) cm^{-1} . MS (ESI +ve) m/z 291 ([M + H] $^+$, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{13}\text{H}_{15}\text{N}_4\text{O}_2\text{S}^+$ 291.0910, found 291.0910 ([M + H] $^+$).

7-(4-(6-methoxybenzo[d]thiazol-2-yl)-1*H*-1,2,3-triazol-1-yl)heptan-1-ol 91. Following General Procedure A₁, alkyne **25** (40 mg, 0.21 mmol), CuSO₄.5H₂O (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **86** (66 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **91** (55 mg, 76%) as a pale yellow solid after preparative TLC plate chromatography (CH₂Cl₂/MeOH – 90:10). TLC (CH₂Cl₂/MeOH – 90:10): R_f = 0.67. Mp 108 °C. ^1H NMR (400 MHz, DMSO) δ 8.87 (s, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.13 (dd, J = 8.8, 2.4 Hz, 1H), 4.46 (t, J = 6.8 Hz, 2H), 4.32 (t, J = 5.2 Hz, 1H), 3.85 (s, 3H), 3.35 (dt, J = 6.8, 5.2 Hz, 2H), 1.89 (quint, J = 6.8 Hz, 2H), 1.42 – 1.25 (m, 8H). ^{13}C NMR (400 MHz, DMSO) δ 157.5, 156.6, 147.6, 142.0, 135.4, 123.2, 123.1, 115.9, 104.9, 60.6, 55.7, 49.9, 32.5, 29.5, 28.3, 25.8, 25.3. IR (neat) ν_{max} 3423 (br), 3128 (w), 2930 (m), 2854 (m), 1609 (m), 1554 (w), 1493 (s), 1436 (s), 1268 (s), 1216 (s), 1070 (s), 1057 (m), 944 (s), 833 (s), 704 (w), 666 (m) cm^{-1} . MS (ESI +ve) m/z 347 ([M + H] $^+$, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{17}\text{H}_{23}\text{N}_4\text{O}_2\text{S}^+$ 347.1536, found 347.1542 ([M + H] $^+$).

8-(4-(6-methoxybenzo[d]thiazol-2-yl)-1*H*-1,2,3-triazol-1-yl)octan-1-ol 92. Following General Procedure A₁, alkyne **25** (40 mg, 0.21 mmol), CuSO₄.5H₂O (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **87** (72 mg, 0.42 mmol) were stirred in *t*-BuOH/H₂O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **92** (56 mg, 74%) as a pale yellow solid after preparative TLC plate chromatography (CH₂Cl₂/MeOH – 90:10). TLC (CH₂Cl₂/MeOH – 90:10): R_f = 0.66. Mp 106 °C. ^1H NMR (400 MHz, DMSO) δ 8.87 (s, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.14 (dd, J = 8.8, 2.4 Hz, 1H), 4.46 (t, J = 6.8 Hz, 2H), 4.30 (t, J = 5.2 Hz, 1H), 3.85 (s, 3H), 3.36 (dt, J = 6.8, 5.2 Hz, 2H), 1.93 – 1.86 (m, 2H), 1.41 – 1.23 (m, 10H). ^{13}C NMR (400 MHz, DMSO) δ 157.5, 156.6, 147.6, 142.0, 135.3, 123.2, 123.1, 115.9, 104.9, 60.7, 55.7, 49.9, 32.5, 29.5, 28.7, 28.4, 25.7, 25.4. IR (neat)

ν_{max} 3425 (br), 3127 (w), 2929 (m), 2852 (m), 1609 (m), 1554 (w), 1493 (s), 1435 (s), 1269 (s), 1215 (s), 1070 (s), 1056 (m), 945 (s), 836 (s), 704 (w), 667 (m) cm^{-1} . MS (ESI +ve) m/z 361 ($[\text{M} + \text{H}]^+$, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{18}\text{H}_{25}\text{N}_4\text{O}_2\text{S}^+$ 361.1693, found 361.1693 ($[\text{M} + \text{H}]^+$).

2-(2-(4-(6-methoxybenzo[*d*]thiazol-2-yl)-1*H*-1,2,3-triazol-1-yl)ethoxy)ethan-1-ol **93.** Following General Procedure A₁, alkyne **25** (40 mg, 0.21 mmol), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (5 mg, 0.02 mmol), sodium ascorbate (8 mg, 0.04 mmol), and azide **88** (55 mg, 0.42 mmol) were stirred in *t*-BuOH/ H_2O (1:1, 4.2 mL) to afford the 1,4-disubstituted-1,2,3-triazole **93** (49 mg, 73%) as a pale yellow solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 90:10). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 90:10): R_f = 0.54. Mp 106 °C. ¹H NMR (400 MHz, CDCl_3) δ 8.38 (s, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.39 (d, J = 2.4 Hz, 1H), 7.09 (dd, J = 8.8, 2.4 Hz, 1H), 4.66 (t, J = 5.2 Hz, 2H), 3.95 (t, J = 5.2 Hz, 2H), 3.89 (s, 3H), 3.76 (t, J = 5.2 Hz, 2H), 3.61 (t, J = 5.2 Hz, 2H), 2.34 (br s, 1H). ¹³C NMR (400 MHz, CDCl_3) δ 158.1, 157.2, 148.2, 143.5, 136.2, 123.5, 122.9, 116.1, 104.3, 72.9, 69.3, 61.8, 56.0, 50.8. IR (neat) ν_{max} 3258 (br), 3153 (w), 2958 (m), 2836 (m), 1608 (m), 1560 (s), 1490 (s), 1431 (s), 1260 (s), 1223 (s), 1062 (s), 1040 (m), 940 (s), 827 (s), 700 (w), 656 (m) cm^{-1} . MS (ESI +ve) m/z 321 ($[\text{M} + \text{H}]^+$, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{14}\text{H}_{17}\text{N}_4\text{O}_3\text{S}^+$ 321.1016, found 321.1021 ($[\text{M} + \text{H}]^+$).

6-methoxybenzo[*d*]thiazole-2-carboxylic acid **95.**¹² To a solution of benzothiazole nitrile **94** (1.00 g, 5.26 mmol) in EtOH (30 mL) was added a solution of 1.0 N NaOH (6.0 mL, 6.00 mmol). The reaction was stirred at reflux for 18 h. The EtOH was removed under reduced pressure at 40 °C, and the minimum volume of H_2O was added to the residue to dissolve completely any solid material. A solution of 18% HCl (1.6 mL) was added until pH reached 3, yielding a yellow precipitate. The resulting precipitate was collected by filtration, washed with H_2O (30 mL), and dried *in vacuo* to afford the benzothiazole carboxylic acid **95** (1.01 g, 92%) as a pale yellow solid. The spectroscopic data was in agreement with that previously reported. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 90:10): R_f = 0.53. ¹H NMR (400 MHz, DMSO) δ 8.06 (d, J = 9.2 Hz, 1H), 7.74 (d, J = 2.0 Hz, 1H), 7.22 (dd, J = 9.2, 2.0 Hz, 1H), 3.86 (s, 3H). ¹³C NMR (400 MHz, DMSO) δ 161.6, 159.0, 158.0, 147.5, 138.3, 125.4, 117.4, 104.5, 55.9. MS (ESI +ve) m/z 208 ($[\text{M} - \text{H}]^-$, 100%).

6-methoxy-N-(6-methylpyridin-3-yl)benzo[*d*]thiazole-2-carboxamide **109.** Following General Procedure C, benzothiazole carboxylic acid **95** (100 mg, 0.48 mmol), amine **96** (52

mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI (119 mg, 0.62 mmol), and DIPEA (334 μ L, 1.92 mmol) were stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide **109** (101 mg, 70%) as a pale yellow solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 97:3). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 97:3): R_f = 0.63. Mp 114 °C. ^1H NMR (400 MHz, DMSO) δ 11.17 (br s, 1H), 8.93 (br s, 1H), 8.15 (dd, J = 8.4, 2.4 Hz, 1H), 8.05 (d, J = 9.2 Hz, 1H), 7.82 (d, J = 2.0 Hz, 1H), 7.29 – 7.23 (m, 2H), 3.88 (s, 3H), 2.45 (s, 3H). ^{13}C NMR (400 MHz, DMSO) δ 161.2, 158.8, 158.5, 153.4, 147.0, 141.5, 138.3, 132.3, 128.4, 124.8, 122.8, 117.4, 102.8, 55.9, 23.4. IR (neat) ν_{max} 3200 (w), 3088 (w), 1652 (m), 1605 (s), 1555 (s), 1492 (s), 1450 (m), 1430 (m), 1330 (m), 1293 (s), 1263 (s), 1226 (m), 1182 (m), 1045 (m), 1026 (m), 876 (m), 835 (m), 741 (m) cm^{-1} . MS (ESI +ve) m/z 300 ([M + H] $^+$, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{15}\text{H}_{14}\text{N}_3\text{O}_2\text{S}^+$ 300.0801, found 300.0807 ([M + H] $^+$).

6-methoxy-N-(pyridin-4-yl)benzo[d]thiazole-2-carboxamide 110. Following General Procedure C, benzothiazole carboxylic acid **95** (100 mg, 0.48 mmol), amine **97** (45 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI (119 mg, 0.62 mmol), and DIPEA (334 μ L, 1.92 mmol) were stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide **110** (105 mg, 77%) as a pale yellow solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 90:10). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 90:10): R_f = 0.46. Mp 220 °C (decomp). ^1H NMR (500 MHz, DMSO) δ 11.41 (s, 1H), 8.52 (d, J = 6.5 Hz, 2H), 8.11 (d, J = 9.0 Hz, 1H), 7.93 (d, J = 6.5 Hz, 2H), 7.84 (d, J = 2.5 Hz, 1H), 7.27 (dd, J = 9.0, 2.5 Hz, 1H), 3.89 (s, 3H). ^{13}C NMR (500 MHz, DMSO) δ 160.8, 159.3, 158.9, 150.4, 147.0, 145.0, 138.5, 125.0, 117.7, 114.5, 104.8, 55.9. IR (neat) ν_{max} 2944 (w), 2840 (w), 2224 (w), 1741 (m), 1682 (m), 1596 (m), 1551 (m), 1495 (s), 1432 (m), 1326 (m), 1275 (m), 1226 (s), 1209 (s), 1187 (m), 1044 (m), 1024 (m), 907 (m), 830 (m), 810 (s) cm^{-1} . MS (ESI +ve) m/z 286 ([M + H] $^+$, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{14}\text{H}_{12}\text{N}_3\text{O}_2\text{S}^+$ 286.0645, found 286.0645 ([M + H] $^+$).

(3-cyanophenyl)-6-methoxybenzo[d]thiazole-2-carboxamide 111. Following General Procedure C, benzothiazole carboxylic acid **95** (100 mg, 0.48 mmol), amine **98** (57 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI (119 mg, 0.62 mmol), and DIPEA (334 μ L, 1.92 mmol) were stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide **111** (111 mg, 75%) as a pale yellow solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 90:10). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 90:10): R_f = 0.39. Mp 168 °C. ^1H NMR (500 MHz, CDCl_3) δ 9.30 (s, 1H), 8.16 (s, 1H), 7.98 (d, J = 9.0 Hz, 1H), 7.95 – 7.93 (m, 1H), 7.50 – 7.46 (m, 2H), 7.40 (d, J = 2.0 Hz, 1H), 7.19 (dd, J = 9.0, 2.5 Hz, 1H), 3.92 (s, 3H). ^{13}C NMR (500 MHz,

CDCl_3) δ 160.2, 159.6, 158.2, 147.2, 139.2, 138.1, 130.3, 128.3, 125.3, 123.9, 122.9, 118.4, 118.0, 113.5, 104.1, 56.0. IR (neat) ν_{max} 3329 (m), 2956 (w), 2224 (m), 1784 (w), 1675 (m), 1589 (m), 1533 (s), 1499 (s), 1426 (s), 1326 (m), 1259 (m), 1237 (m), 1218 (s), 1188 (m), 1044 (m), 1023 (m), 886 (m), 849 (s), 789 (s), 674 (s) cm^{-1} . MS (ESI -ve) m/z 308 ($[\text{M} - \text{H}]^-$, 100%). HRMS (ESI -ve TOF) calcd for $\text{C}_{16}\text{H}_{10}\text{N}_3\text{O}_2\text{S}^-$ 308.0499, found 308.0488 ($[\text{M} - \text{H}]^-$).

N-(5-fluoropyridin-3-yl)-6-methoxybenzo[d]thiazole-2-carboxamide 112. Following General Procedure C, benzothiazole carboxylic acid **95** (100 mg, 0.48 mmol), amine **99** (54 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI (119 mg, 0.62 mmol), and DIPEA (334 μL , 1.92 mmol) were stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide **112** (106 mg, 73%) as a pale yellow solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5): R_f = 0.60. Mp 204 °C. ^1H NMR (500 MHz, DMSO) δ 11.37 (br s, 1H), 8.72 (s, 1H), 8.46 – 8.41 (m, 1H), 8.09 (d, J = 9.2 Hz, 1H), 7.83 (d, J = 2.0 Hz, 1H), 7.27 – 7.22 (m, 2H), 3.88 (s, 3H). ^{13}C NMR (125 MHz, DMSO) δ 160.9, 159.2 (d, $^1J_{\text{CF}} = 232.5$ Hz), 158.8, 158.7, 147.0, 139.5 (d, $^2J_{\text{CF}} = 15.6$ Hz), 138.4, 134.3, 133.2, 124.9, 117.6, 109.4 (d, $^2J_{\text{CF}} = 39.1$ Hz), 104.8, 55.9. IR (neat) ν_{max} 3254 (br), 3066 (w), 1686 (m), 1590 (m), 1540 (s), 1499 (s), 1448 (m), 1426 (m), 1333 (m), 1312 (s), 1296 (s), 1247 (s), 1228 (m), 1124 (m), 1048 (m), 1018 (m), 871 (m), 727 (s) cm^{-1} . MS (ESI +ve) m/z 304 ($[\text{M} + \text{H}]^+$, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{14}\text{H}_{11}\text{FN}_3\text{O}_2\text{S}^+$ 304.0551, found 304.0556 ($[\text{M} + \text{H}]^+$).

N-(4-fluoropyridin-2-yl)-6-methoxybenzo[d]thiazole-2-carboxamide 113. Following General Procedure C, benzothiazole carboxylic acid **95** (100 mg, 0.48 mmol), amine **100** (54 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI (119 mg, 0.62 mmol), and DIPEA (334 μL , 1.92 mmol) were stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide **113** (110 mg, 76%) as a pale yellow solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5): R_f = 0.61. Mp 202 °C. ^1H NMR (500 MHz, DMSO) δ 10.61 (br s, 1H), 8.49 – 8.47 (m, 1H), 8.12 (d, J = 9.2 Hz, 1H), 7.97 – 7.94 (m, 1H), 7.87 (d, J = 2.0 Hz, 1H), 7.28 (dd, J = 9.2, 2.0 Hz, 1H), 7.22 – 7.18 (m, 1H), 3.89 (s, 3H). ^{13}C NMR (125 MHz, DMSO) δ 169.0 (d, $^1J_{\text{CF}} = 255.8$ Hz), 159.9, 159.0, 158.6, 152.7, 151.3, 146.8, 138.7, 125.2, 117.8, 108.7 (d, $^2J_{\text{CF}} = 17.4$ Hz), 104.9, 101.7 (d, $^2J_{\text{CF}} = 23.4$ Hz), 55.9. IR (neat) ν_{max} 3179 (br), 3071 (w), 1668 (m), 1595 (m), 1555 (s), 1507 (s), 1466 (m), 1427 (m), 1416 (m), 1329 (s), 1297 (s), 1258 (s), 1220 (m), 1130 (m), 1043 (m), 1016 (m), 857 (m), 767 (s) cm^{-1} .

MS (ESI +ve) m/z 304 ($[M + H]^+$, 100%). HRMS (ESI +ve TOF) calcd for $C_{14}H_{11}FN_3O_2S^+$ 304.0551, found 304.0556 ($[M + H]^+$).

N-(6-fluoropyridin-3-yl)-6-methoxybenzo[d]thiazole-2-carboxamide 114. Following **General Procedure C**, benzothiazole carboxylic acid **95** (100 mg, 0.48 mmol), amine **101** (54 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI (119 mg, 0.62 mmol), and DIPEA (334 μ L, 1.92 mmol) were stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide **114** (112 mg, 77%) as a brown solid after preparative TLC plate chromatography ($CH_2Cl_2/MeOH - 95:5$). TLC ($CH_2Cl_2/MeOH - 95:5$): $R_f = 0.66$. Mp 202 °C. 1H NMR (500 MHz, DMSO) δ 11.50 (br s, 1H), 8.98 (s, 1H), 8.35 – 8.31 (m, 1H), 8.26 – 8.22 (m, 1H), 8.09 (d, $J = 9.2$ Hz, 1H), 7.82 (d, $J = 2.0$ Hz, 1H), 7.25 (dd, $J = 9.2, 2.0$ Hz), 3.88 (s, 3H). ^{13}C NMR (125 MHz, DMSO) δ 160.7, 158.5 (d, $^1J_{CF} = 252.0$ Hz), 159.0, 158.9, 147.0, 138.5, 138.4, 136.1, 132.8 (d, $^2J_{CF} = 30.0$ Hz), 125.0, 117.6, 114.4 (d, $^3J_{CF} = 22.5$ Hz), 104.8, 55.9. IR (neat) ν_{max} 3234 (br), 3052 (w), 1656 (m), 1603 (m), 1532 (s), 1499 (s), 1449 (m), 1429 (m), 1381 (m), 1331 (m), 1298 (s), 1271 (s), 1220 (m), 1121 (m), 1045 (m), 1022 (m), 870 (m), 733 (s) cm^{-1} . MS (ESI +ve) m/z 304 ($[M + H]^+$, 100%). HRMS (ESI +ve TOF) calcd for $C_{14}H_{11}FN_3O_2S^+$ 304.0551, found 304.0556 ($[M + H]^+$).

N-(4-(hydroxymethyl)phenyl)-6-methoxybenzo[d]thiazole-2-carboxamide 115. Following **General Procedure C**, benzothiazole carboxylic acid **95** (100 mg, 0.48 mmol), amine **102** (59 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI (119 mg, 0.62 mmol), and DIPEA (334 μ L, 1.92 mmol) were stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide **115** (112 mg, 71%) as a pale yellow solid after preparative TLC plate chromatography ($CH_2Cl_2/MeOH - 90:10$). TLC ($CH_2Cl_2/MeOH - 90:10$): $R_f = 0.35$. Mp 158 °C (decomp). 1H NMR (400 MHz, $CDCl_3$) δ 10.93 (s, 1H), 8.08 (d, $J = 9.2$ Hz, 1H), 7.84 (d, $J = 8.4$ Hz, 2H), 7.81 (d, $J = 2.4$ Hz, 1H), 7.32 (d, $J = 8.4$ Hz, 2H), 7.25 (dd, $J = 9.2, 2.4$ Hz, 1H), 5.14 (t, $J = 5.6$ Hz, 1H), 4.48 (d, $J = 5.6$ Hz, 2H), 3.88 (s, 3H). ^{13}C NMR (400 MHz, $CDCl_3$) δ 161.9, 158.6, 158.1, 147.1, 138.6, 138.3, 136.5, 126.8, 124.8, 120.4, 117.3, 104.8, 62.6, 55.8. IR (neat) ν_{max} 3452 (br), 3258 (br), 1645 (m), 1596 (m), 1529 (s), 1494 (s), 1412 (m), 1332 (m), 1269 (m), 1223 (s), 1186 (m), 1048 (m), 1018 (m), 977 (m), 910 (m), 876 (m), 824 (s), 733 (m) cm^{-1} . MS (ESI +ve) m/z 315 ($[M + H]^+$, 100%). HRMS (ESI +ve TOF) calcd for $C_{16}H_{15}N_2O_3S^+$ 315.0798, found 315.0798 ($[M + H]^+$).

6-methoxy-N-((6-methylpyridin-3-yl)methyl)benzo[d]thiazole-2-carboxamide 116. Following **General Procedure C**, benzothiazole carboxylic acid **95** (100 mg, 0.48 mmol),

amine **103** (59 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI (119 mg, 0.62 mmol), and DIPEA (334 μ L, 1.92 mmol) were stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide **116** (123 mg, 82%) as a pale yellow solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5): $R_f = 0.71$. Mp 201 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.44 (br s, 1H), 8.32 (br s, 1H), 7.96 (dd, $J = 8.4, 2.4$ Hz, 1H), 7.49 (d, $J = 9.2$ Hz, 1H), 7.37 (d, $J = 2.0$ Hz, 1H), 7.26 (d, $J = 8.4$ Hz, 1H), 7.14 (dd, $J = 9.2, 2.0$ Hz, 1H), 4.76 (d, $J = 6.0$ Hz, 2H) 3.90 (s, 3H), 2.34 (s, 3H). ^{13}C NMR (400 MHz, CDCl_3) δ 161.1, 160.3, 159.0, 153.4, 149.9, 147.7, 139.0, 137.6, 132.2, 125.2, 121.7, 117.2, 104.0, 56.0, 44.7, 18.3. IR (neat) ν_{max} 3366 (m), 3300 (w), 1657 (s), 1604 (m), 1516 (s), 1497 (s), 1448 (m), 1428 (m), 1326 (s), 1263 (s), 1226 (m), 1226 (m), 1183 (m), 1058 (s), 1023 (m), 872 (m), 822 (s), 764 (m) cm^{-1} . MS (ESI +ve) m/z 314 ([M + H] $^+$, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{16}\text{H}_{16}\text{N}_3\text{O}_2\text{S}^+$ 314.0958, found 314.0963 ([M + H] $^+$).

N-benzyl-6-methoxybenzo[d]thiazole-2-carboxamide 117. Following General Procedure C, benzothiazole carboxylic acid **95** (100 mg, 0.48 mmol), amine **104** (51 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI (119 mg, 0.62 mmol), and DIPEA (334 μ L, 1.92 mmol) were stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide **117** (122 mg, 85%) as a white solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 98:2). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 98:2): $R_f = 0.76$. Mp 155°C. ^1H NMR (400 MHz, CDCl_3) δ 7.89 (d, $J = 9.2$ Hz, 1H), 7.67 (br s, 1H), 7.40 – 7.30 (m, 5H), 7.13 (dd, $J = 9.2, 2.0$ Hz, 1H), 4.68 (d, $J = 6.0$ Hz, 2H) 3.90 (s, 3H). ^{13}C NMR (400 MHz, CDCl_3) δ 161.1, 160.1, 159.1, 147.5, 139.0, 137.6, 129.0, 128.2, 127.9, 125.0, 117.4, 104.0, 56.0, 44.0. IR (neat) ν_{max} 3363 (w), 3296 (w), 1656 (s), 1603 (m), 1526 (s), 1495 (s), 1457 (m), 1428 (m), 1328 (m), 1265 (s), 1249 (m), 1228 (m), 1187 (m), 1055 (m), 1023 (m), 894 (m), 831 (s), 764 (s) cm^{-1} . MS (ESI +ve) m/z 299 ([M + H] $^+$, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{16}\text{H}_{15}\text{N}_2\text{O}_2\text{S}^+$ 299.0849, found 299.0854 ([M + H] $^+$).

6-methoxy-N-(3-methylbenzyl)benzo[d]thiazole-2-carboxamide 118. Following General Procedure C, benzothiazole carboxylic acid **95** (100 mg, 0.48 mmol), amine **105** (58 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI (119 mg, 0.62 mmol), and DIPEA (334 μ L, 1.92 mmol) were stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide **118** (125 mg, 83%) as a pale yellow solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 98:2). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 98:2): $R_f = 0.77$. Mp 99 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.88 (d, $J = 9.2$ Hz, 1H), 7.64 (br s, 1H), 7.37 – 7.05 (m, 6H), 4.63 (s, 2H), 3.89 (s, 3H), 2.35 (s,

3H). ^{13}C NMR (400 MHz, CDCl_3) δ 161.2, 160.1, 159.1, 147.5, 139.0, 138.7, 137.5, 128.9, 128.8, 128.7, 125.2, 125.0, 117.3, 104.0, 56.0, 44.0, 21.5. IR (neat) ν_{max} 3363 (w), 3296 (w), 1656 (s), 1603 (m), 1528 (s), 1495 (s), 1457 (m), 1431 (m), 1327 (m), 1263 (s), 1252 (m), 1227 (m), 1187 (m), 1055 (m), 1021 (m), 897 (s), 831 (s), 763 (s) cm^{-1} . MS (ESI +ve) m/z 313 ([M + H] $^+$, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{17}\text{H}_{17}\text{N}_2\text{O}_2\text{S}^+$ 313.1005, found 313.1011 ([M + H] $^+$).

N-(4-fluorobenzyl)-6-methoxybenzo[d]thiazole-2-carboxamide 119. Following General Procedure C, benzothiazole carboxylic acid **95** (100 mg, 0.48 mmol), amine **106** (60 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI (119 mg, 0.62 mmol), and DIPEA (334 μL , 1.92 mmol) were stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide **119** (115 mg, 76%) as a yellow solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5): R_f = 0.63. Mp 103 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.88 (d, J = 8.8 Hz, 1H), 7.70 (br s, 1H), 7.37 – 7.32 (m, 3H), 7.13 (dd, J = 8.8, 2.4 Hz, 1H), 7.05 – 7.01 (m, 2H), 4.64 (d, J = 6.4 Hz, 2H), 3.89 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 162.4 (d, $^1J_{\text{CF}}$ = 244.6 Hz), 160.9, 160.0, 159.0, 147.4, 138.9, 133.4, 129.7 (d, $^3J_{\text{CF}}$ = 8.1 Hz), 124.9, 117.3, 156.7 (d, $^2J_{\text{CF}}$ = 21.2 Hz), 103.9, 55.9, 43.2. IR (neat) ν_{max} 33365 (m), 3010 (w), 1653 (s), 1603 (m), 1556 (s), 1456 (s), 1440 (m), 1425 (m), 1328 (m), 1304 (s), 1282 (s), 1255 (s), 1217 (m), 1118 (m), 1058 (m), 1025 (m), 848 (m), 747 (s) cm^{-1} . MS (ESI +ve) m/z 317 ([M + H] $^+$, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{16}\text{H}_{14}\text{FN}_2\text{O}_2\text{S}^+$ 317.0755, found 317.0760 ([M + H] $^+$).

N-(3-fluorobenzyl)-6-methoxybenzo[d]thiazole-2-carboxamide 120. Following General Procedure C, benzothiazole carboxylic acid **95** (100 mg, 0.48 mmol), amine **107** (60 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI (119 mg, 0.62 mmol), and DIPEA (334 μL , 1.92 mmol) were stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide **120** (103 mg, 68%) as a pale yellow solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5): R_f = 0.69. Mp 122 °C. ^1H NMR (400 MHz, DMSO) δ 9.67 (t, J = 6.4 Hz, 1H), 8.01 (d, J = 9.2 Hz, 1H), 7.78 (d, J = 2.4 Hz, 1H), 7.40 – 7.35 (m, 1H), 7.25 – 7.15 (m, 3H), 7.10 – 7.06 (m, 1H), 4.50 (d, J = 6.4 Hz, 2H), 3.87 (s, 3H). ^{13}C NMR (100 MHz, DMSO) δ 162.2 (d, $^1J_{\text{CF}}$ = 242.0 Hz), 161.4, 159.7, 158.5, 147.1, 141.9 (d, $^3J_{\text{CF}}$ = 7.0 Hz), 138.0, 130.3 (d, $^3J_{\text{CF}}$ = 8.4 Hz), 124.6, 123.42 (d, $^4J_{\text{CF}}$ = 2.4 Hz), 117.2, 114.1 (d, $^2J_{\text{CF}}$ = 21.7 Hz), 113.7 (d, $^2J_{\text{CF}}$ = 20.7 Hz), 104.8, 55.8, 42.2. IR (neat) ν_{max} 3303 (m), 1655 (s), 1603 (m), 1589 (s), 1530 (s), 1495 (s), 1466 (m), 1448 (m), 1328 (m), 1301 (s), 1270 (s), 1248 (s), 1229 (m), 1149 (m), 1055 (m), 1023 (m), 888 (m), 831 (m), 733 (m) cm^{-1} . MS (ESI +ve) m/z

317 ($[M + H]^+$, 100%). HRMS (ESI +ve TOF) calcd for $C_{16}H_{14}FN_2O_2S^+$ 317.0755, found 317.0760 ($[M + H]^+$).

6-methoxy-N-(4-(trifluoromethyl)benzyl)benzo[d]thiazole-2-carboxamide 121. Following General Procedure C, benzothiazole carboxylic acid **95** (100 mg, 0.48 mmol), amine **108** (84 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI (119 mg, 0.62 mmol), and DIPEA (334 μ L, 1.92 mmol) were stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide **121** (129 mg, 73%) as a pale yellow solid after preparative TLC plate chromatography ($CH_2Cl_2/MeOH - 95:5$). TLC ($CH_2Cl_2/MeOH - 95:5$): $R_f = 0.71$. Mp 123 °C. 1H NMR (400 MHz, DMSO) δ 9.74 (t, $J = 6.4$ Hz, 1H), 8.01 (d, $J = 9.2$ Hz, 1H), 7.78 (d, $J = 2.8$ Hz, 1H), 7.70 (d, $J = 8.0$ Hz, 2H), 7.57 (d, $J = 8.0$ Hz, 2H), 7.22 (dd, $J = 9.2, 2.8$ Hz, 1H), 4.57 (d, $J = 6.4$ Hz, 2H), 3.87 (s, 3H). ^{13}C NMR (100 MHz, DMSO) δ 161.3, 159.8, 158.5, 147.1, 143.8, 138.0, 128.1, 127.7 (q, $^2J_{CF} = 31.8$ Hz), 126.5 (q, $^3J_{CF} = 3.5$ Hz), 125.2 (q, $^1J_{CF} = 270.4$ Hz), 124.6, 117.2, 104.8, 55.8, 42.4. IR (neat) ν_{max} 3392 (m), 1676 (m), 1620 (m), 1602 (s), 1554 (s), 1494 (s), 1453 (m), 1436 (m), 1332 (m), 1300 (s), 1270 (s), 1247 (s), 1224 (m), 1150 (m), 1056 (m), 1015 (m), 848 (m), 831 (m), 747 (m) cm^{-1} . MS (ESI +ve) m/z 367 ($[M + H]^+$, 100%). HRMS (ESI +ve TOF) calcd for $C_{17}H_{14}F_3N_2O_2S^+$ 367.0723, found 367.0728 ($[M + H]^+$).

Sodium 6-methoxybenzo[d]thiazole-2-carboxylate 122.¹³ To a solution of benzothiazole carboxylic acid **95** (500 mg, 2.39 mmol) in MeOH (25 mL) was added a solution of 0.1 M NaOH (25 mL, 2.50 mmol), and the reaction was stirred at rt for 2 h. The solvents were removed under reduced pressure at 40 °C, and the resulting material suspended in H_2O (1.0 mL) and EtOH (5.0 mL), and evaporated to dryness. The solid was dissolved in CH_2Cl_2 , and evaporated to afford the benzothiazole salt **122** (520 mg, 98%) as a pale yellow solid. The spectroscopic data was in agreement with that previously reported. TLC ($CH_2Cl_2/MeOH - 90:10$): $R_f = 0.73$. 1H NMR (400 MHz, DMSO) δ 7.92 (d, $J = 8.8$ Hz, 1H), 7.57 (d, $J = 2.8$ Hz, 1H), 7.09 (dd, $J = 8.8, 2.8$ Hz, 1H), 3.82 (s, 3H). ^{13}C NMR (400 MHz, DMSO) δ 170.1, 162.0, 157.6, 147.7, 138.0, 124.2, 115.4, 104.4, 55.6. MS (ESI) m/z 231 ([M], 100%).

4-cyanobenzyl 6-methoxybenzo[d]thiazole-2-carboxylate 127. Following General Procedure D, benzothiazole salt **122** (90 mg, 0.39 mmol) and alkyl bromide **123** (76 mg, 0.39 mmol) were stirred in anhydrous DMF (3.9 mL) for 24 h to afford the ester **127** (108 mg, 85%) as a yellow solid after preparative TLC plate chromatography ($CH_2Cl_2/MeOH - 97:3$). TLC ($CH_2Cl_2/MeOH - 97:3$): $R_f = 0.79$. Mp 120 °C. 1H NMR (500 MHz, $CDCl_3$) δ 8.11 (d, $J = 8.8$ Hz, 1H), 7.70 (d, $J = 8.0$ Hz, 2H), 7.61 (d, $J = 8.0$ Hz, 2H), 7.36 (d, $J = 2.8$ Hz, 1H), 7.19 (dd,

J = 8.8, 2.8 Hz, 1H), 5.53 (s, 2H), 3.91 (s, 3H). ^{13}C NMR (500 MHz, CDCl_3) δ 160.6, 160.0, 154.5, 148.0, 140.4, 139.0, 132.9, 128.9, 126.4, 118.6, 118.1, 112.7, 103.5, 67.0, 56.0. IR (neat) ν_{max} 2944 (w), 2840 (w), 2224 (m), 1741 (s), 1682 (w), 1604 (m), 1547 (m), 1494 (s), 1452 (m), 1325 (m), 1274 (m), 1236 (s), 1221 (m), 1179 (m), 1056 (m), 1028 (m), 903 (m), 858 (m), 830 (s), 751 (m) cm^{-1} . MS (ESI +ve) *m/z* 325 ([M + H]⁺, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{17}\text{H}_{13}\text{N}_2\text{O}_3\text{S}^+$ 325.0641, found 325.0613 ([M + H]⁺).

3-fluorobenzyl 6-methoxybenzo[*d*]thiazole-2-carboxylate 128. Following General Procedure D, benzothiazole salt **122** (90 mg, 0.39 mmol) and alkyl bromide **124** (74 mg, 0.39 mmol) were stirred in anhydrous DMF (3.9 mL) for 24 h to afford the ester **128** (109 mg, 88%) as a pale yellow solid after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5): R_f = 0.71. Mp 89 °C. ^1H NMR (500 MHz, DMSO) δ 8.10 (d, *J* = 8.8 Hz, 1H), 7.80 – 7.78 (m, 1H), 7.50 – 7.46 (m, 1H), 7.38 – 7.34 (m, 2H), 7.25 – 7.21 (m, 2H), 5.45 (s, 2H), 3.86 (s, 3H). ^{13}C NMR (125 MHz, DMSO) δ 162.2 (d, $^1J_{\text{CF}} = 242.8$ Hz), 159.9, 159.4, 154.8, 147.3, 138.3, 138.0 (d, $^3J_{\text{CF}} = 7.6$ Hz), 130.8, 125.8, 124.5, 118.0, 115.3 (d, $^2J_{\text{CF}} = 43.0$ Hz), 115.3, 104.5, 66.9, 56.0. IR (neat) ν_{max} 3667 (w), 2951 (w), 2224 (w), 1740 (s), 1690 (m), 1599 (m), 1552 (m), 1493 (s), 1452 (m), 1433 (m), 1378 (m), 1331 (m), 1306 (m), 1247 (m), 1224 (s), 1180 (s), 1047 (m), 1024 (m), 956 (s), 873 (m), 738 (s) cm^{-1} . MS (ESI +ve) *m/z* 318 ([M + H]⁺, 100%), 340 ([M + Na]⁺, 20%). HRMS (ESI +ve TOF) calcd for $\text{C}_{16}\text{H}_{13}\text{FNO}_3\text{S}^+$ 318.0595, found 318.0595 ([M + H]⁺).

4-(trifluoromethyl)benzyl 6-methoxybenzo[*d*]thiazole-2-carboxylate 129. Following General Procedure D, benzothiazole salt **122** (90 mg, 0.39 mmol) and alkyl bromide **125** (93 mg, 0.39 mmol) were stirred in anhydrous DMF (3.9 mL) for 24 h to afford the ester **129** (112 mg, 78%) as a pale yellow crystal after preparative TLC plate chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5). TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ – 95:5): R_f = 0.81. Mp 106 °C. ^1H NMR (500 MHz, DMSO) δ 8.11 (d, *J* = 8.8 Hz, 1H), 7.82 – 7.79 (m, 3H), 7.73 (d, *J* = 8.0 Hz, 2H), 7.25 (dd, *J* = 8.8, 2.4 Hz, 1H), 5.55 (s, 2H), 3.87 (s, 3H). ^{13}C NMR (125 MHz, DMSO) δ 159.9, 159.4, 154.7, 147.3, 140.1, 138.4, 128.9, 127.7 (q, $^2J_{\text{CF}} = 32.0$ Hz), 126.6 (q, $^3J_{\text{CF}} = 3.2$ Hz), 125.8, 125.6 (q, $^1J_{\text{CF}} = 270.4$ Hz), 118.0, 104.5, 66.8, 56.0. IR (neat) ν_{max} 2965 (w), 2926 (w), 2840 (w), 1700 (m), 1600 (m), 1550 (m), 1498 (s), 1455 (m), 1434 (m), 1419 (m), 1381 (m), 1326 (s), 1305 (m), 1244 (s), 1223 (m), 1116 (s), 1107 (s), 1092 (s), 1066 (s), 1048 (s), 829 (s), 760 (m), 737 (m) cm^{-1} . MS (ESI +ve) *m/z* 368 ([M + H]⁺, 100%). HRMS (ESI +ve TOF) calcd for $\text{C}_{17}\text{H}_{13}\text{F}_3\text{NO}_3\text{S}^+$ 368.0563, found 368.0616 ([M + H]⁺).

4-nitrophenethyl 6-methoxybenzo[d]thiazole-2-carboxylate 130. Following General Procedure D, benzothiazole salt **122** (90 mg, 0.39 mmol) and alkyl bromide **126** (90 mg, 0.39 mmol) were stirred in anhydrous DMF (3.9 mL) for 24 h to afford the ester **130** (105 mg, 75%) as a pale yellow solid after preparative TLC plate chromatography (CH₂Cl₂/MeOH – 97:3). TLC (CH₂Cl₂/MeOH – 97:3): R_f = 0.77. Mp 130 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, J = 8.4 Hz, 2H), 8.11 (d, J = 8.8 Hz, 1H), 7.48 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 2.4 Hz, 1H), 7.19 (dd, J = 8.8, 2.4 Hz, 1H), 4.71 (t, J = 7.2 Hz, 2H), 3.91 (s, 3H), 3.27 (t, J = 7.2 Hz, 2H). ¹³C NMR (400 MHz, CDCl₃) δ 160.5, 160.0, 154.7, 148.0, 147.2, 145.1, 138.9, 130.1, 126.4, 124.0, 118.0, 103.5, 66.0, 56.0, 35.1. IR (neat) ν_{max} 3122 (w), 2900 (w), 1609 (m), 1554 (s), 1520 (s), 1490 (m), 1433 (m), 1377 (m), 1356 (m), 1310 (m), 1270 (s), 1214 (m), 1159 (m), 1059 (m), 1025 (m), 898 (m), 811 (m) cm⁻¹. MS (ESI +ve) m/z 359 ([M + H]⁺, 100%). HRMS (ESI +ve TOF) calcd for C₁₇H₁₅N₂O₅S⁺ 359.0696, found 359.0697 ([M + H]⁺).

3. ^1H NMR and ^{13}C NMR Spectra of Final Compounds

Figure S1. ^1H NMR for **30** (400 MHz, DMSO- d_6)




Figure S2. ^{13}C NMR for **30** (400 MHz, DMSO- d_6)




Figure S3. ¹H NMR for **31** (400 MHz, DMSO-*d*₆)




Figure S4. ¹³C NMR for **31** (400 MHz, DMSO-*d*₆)




Figure S5. ^1H NMR for **32** (500 MHz, $\text{DMSO}-d_6$)




Figure S6. ^{13}C NMR for **32** (500 MHz, $\text{DMSO}-d_6$)




Figure S7. ^1H NMR for **64** (500 MHz, $\text{DMSO}-d_6$)




Figure S8. ^{13}C NMR for **64** (125 MHz, $\text{DMSO}-d_6$)




Figure S9. ^1H NMR for **65** (400 MHz, $\text{DMSO}-d_6$)




Figure S10. ^{13}C NMR for **65** (100 MHz, $\text{DMSO}-d_6$)




Figure S11. ¹H NMR for **66** (400 MHz, DMSO-*d*₆)




Figure S12. ¹³C NMR for **66** (100 MHz, DMSO-*d*₆)




Figure S13. ¹H NMR for **67** (400 MHz, DMSO-*d*₆)




Figure S14. ¹³C NMR for **67** (100 MHz, DMSO-*d*₆)




Figure S15. ¹H NMR for **68** (500 MHz, DMSO-*d*₆)




Figure S16. ¹³C NMR for **68** (125 MHz, DMSO-*d*₆)




Figure S17. ^1H NMR for **69** (500 MHz, $\text{DMSO}-d_6$)




Figure S18. ^{13}C NMR for **69** (500 MHz, $\text{DMSO}-d_6$)




Figure S19. ¹H NMR for **70** (400 MHz, DMSO-*d*₆)




Figure S20. ¹³C NMR for **70** (400 MHz, DMSO-*d*₆)




Figure S21. ^1H NMR for **71** (400 MHz, $\text{DMSO}-d_6$)




Figure S22. ^{13}C NMR for **71** (500 MHz, $\text{DMSO}-d_6$)




Figure S23. ^1H NMR for **72** (400 MHz, $\text{DMSO}-d_6$)




Figure S24. ^{13}C NMR for **72** (400 MHz, $\text{DMSO}-d_6$)




Figure S25. ^1H NMR for **73** (400 MHz, $\text{DMSO}-d_6$)




Figure S26. ^{13}C NMR for **73** (400 MHz, $\text{DMSO}-d_6$)




Figure S27. ^1H NMR for **74** (400 MHz, $\text{DMSO}-d_6$)




Figure S28. ^{13}C NMR for **74** (100 MHz, $\text{DMSO}-d_6$)




Figure S29. ^1H NMR for **75** (400 MHz, $\text{DMSO}-d_6$)




Figure S30. ^{13}C NMR for **75** (100 MHz, $\text{DMSO}-d_6$)




Figure S31. ^1H NMR for **76** (400 MHz, $\text{DMSO}-d_6$)




Figure S32. ^{13}C NMR for **76** (100 MHz, $\text{DMSO}-d_6$)




Figure S33. ^1H NMR for 77 (400 MHz, $\text{DMSO}-d_6$)




Figure S34. ^{13}C NMR for 77 (400 MHz, $\text{DMSO}-d_6$)




Figure S35. ¹H NMR for **78** (500 MHz, DMSO-*d*₆)




Figure S36. ^{13}C NMR for **78** (500 MHz, $\text{DMSO}-d_6$)




Figure S37. ^1H NMR for **89** (400 MHz, $\text{DMSO}-d_6$)




Figure S38. ^{13}C NMR for **89** (400 MHz, $\text{DMSO}-d_6$)




Figure S39. ^1H NMR for **90** (400 MHz, $\text{DMSO}-d_6$)




Figure S40. ^{13}C NMR for **90** (400 MHz, $\text{DMSO}-d_6$)




Figure S41. ^1H NMR for **91** (400 MHz, $\text{DMSO}-d_6$)




Figure S42. ^{13}C NMR for **91** (400 MHz, $\text{DMSO}-d_6$)




Figure S43. ^1H NMR for **92** (400 MHz, $\text{DMSO}-d_6$)




Figure S44. ^{13}C NMR for **92** (400 MHz, $\text{DMSO}-d_6$)




Figure S45. ^1H NMR for **93** (400 MHz, CDCl_3)




Figure S46. ^{13}C NMR for **93** (400 MHz, CDCl_3)




Figure S47. ^1H NMR for **109** (400 MHz, $\text{DMSO}-d_6$)




Figure S48. ^{13}C NMR for **109** (400 MHz, DMSO- d_6)




Figure S49. ^1H NMR for **110** (500 MHz, DMSO- d_6)




Figure S50. ^{13}C NMR for **110** (500 MHz, $\text{DMSO}-d_6$)




Figure S51. ^1H NMR for **111** (500 MHz, CDCl_3)




Figure S52. ^{13}C NMR for **111** (500 MHz, CDCl_3)




Figure S53. ^1H NMR for **112** (500 MHz, $\text{DMSO}-d_6$)




Figure S54. ^{13}C NMR for **112** (125 MHz, DMSO- d_6)




Figure S55. ^1H NMR for **113** (500 MHz, DMSO- d_6)




Figure S56. ^{13}C NMR for **113** (125 MHz, $\text{DMSO}-d_6$)




Figure S57. ^1H NMR for **114** (500 MHz, $\text{DMSO}-d_6$)




Figure S58. ^{13}C NMR for **114** (125 MHz, $\text{DMSO}-d_6$)




Figure S59. ^1H NMR for **115** (400 MHz, CDCl_3)




Figure S60. ^{13}C NMR for **115** (400 MHz, CDCl_3)




Figure S61. ^1H NMR for **116** (400 MHz, CDCl_3)




Figure S62. ^{13}C NMR for **116** (400 MHz, CDCl_3)




Figure S63. ^1H NMR for **117** (400 MHz, CDCl_3)




Figure S64. ^{13}C NMR for **117** (400 MHz, CDCl_3)




Figure S65. ^1H NMR for **118** (400 MHz, CDCl_3)




Figure S66. ^{13}C NMR for **118** (400 MHz, CDCl_3)




Figure S67. ^1H NMR for **119** (400 MHz, CDCl_3)




Figure S68. ^{13}C NMR for **119** (100 MHz, CDCl_3)




Figure S69. ^1H NMR for **120** (400 MHz, $\text{DMSO}-d_6$)




Figure S70. ^{13}C NMR for **120** (100 MHz, $\text{DMSO}-d_6$)




Figure S71. ^1H NMR for **121** (400 MHz, $\text{DMSO}-d_6$)




Figure S72. ^{13}C NMR for **121** (100 MHz, $\text{DMSO}-d_6$)




Figure S73. ^1H NMR for **127** (500 MHz, CDCl_3)




Figure S74. ^{13}C NMR for **127** (500 MHz, CDCl_3)




Figure S75. ^1H NMR for **128** (500 MHz, $\text{DMSO}-d_6$)




Figure S76. ^{13}C NMR for **128** (125 MHz, $\text{DMSO}-d_6$)




Figure S75. ^1H NMR for **129** (500 MHz, $\text{DMSO}-d_6$)




Figure S76. ^{13}C NMR for **129** (125 MHz, $\text{DMSO}-d_6$)




Figure S75. ^1H NMR for **130** (400 MHz, CDCl_3)






Figure S76. ^{13}C NMR for **130** (400 MHz, CDCl_3)




4. ^1H NMR and ^{13}C NMR Spectra of Key Intermediates


^1H NMR for **23** (400 MHz, CDCl_3)




¹³C NMR for 23 (400 MHz, CDCl₃)




¹H NMR for 24 (400 MHz, CDCl₃)




¹³C NMR for **24** (400 MHz, CDCl₃)




¹H NMR for **25** (400 MHz, CDCl₃)




¹³C NMR for **25** (400 MHz, CDCl_3)




¹H NMR for **27** (400 MHz, CDCl_3)






¹H NMR for **27** (400 MHz, CDCl₃)




¹H NMR for the mixture of **28** and **27** (400 MHz, CDCl₃)




¹H NMR for **29** (400 MHz, CDCl₃)




^{13}C NMR for **29** (400 MHz, CDCl_3)




^1H NMR for **35** (400 MHz, CD_3OD)




¹H NMR for **35** (400 MHz, DMSO-*d*₆)




¹H NMR for **41** (400 MHz, CDCl₃)




¹H NMR for **41** (400 MHz, CDCl₃)




¹H NMR for **42** (400 MHz, CDCl₃)




¹³C NMR for **42** (400 MHz, CDCl₃)




¹H NMR for **43** (400 MHz, CDCl₃)




¹³C NMR for **43** (400 MHz, CDCl₃)




¹H NMR for **54** (400 MHz, CDCl₃)




¹³C NMR for 54 (100 MHz, CDCl₃)




¹H NMR for 55 (400 MHz, CDCl₃)




¹³C NMR for **55** (100 MHz, CDCl₃)





¹H NMR for **56** (400 MHz, CDCl₃)





¹H NMR for **56** (400 MHz, CDCl₃)



¹H NMR for **57** (400 MHz, CDCl₃)




¹H NMR for **58** (400 MHz, CDCl₃)




¹³C NMR for **58** (400 MHz, CDCl_3)


—147.69
—142.84
—128.60
—123.97
—77.48
—77.16
—76.84
—53.68





¹H NMR for **59** (400 MHz, CDCl_3)



¹³C NMR for **59** (400 MHz, CDCl₃)





¹H NMR for **60** (400 MHz, CDCl₃)




^{13}C NMR for **60** (100 MHz, CDCl_3)


— 163.18
— 160.75
— 133.88
— 133.84
— 130.39
— 130.32
— 115.22
— 115.51
— 77.48
— 77.36
— 77.16
— 76.84
— 52.64
— -54.71




^1H NMR for **61** (500 MHz, CDCl_3)





¹H NMR for **62** (400 MHz, CDCl₃)



¹³C NMR for **62** (400 MHz, CDCl₃)





¹H NMR for **63** (400 MHz, CDCl₃)



^{13}C NMR for **63** (400 MHz, CDCl_3)

Peak labels (ppm): 147.08, 145.94, 129.80, 123.94, 77.41, 77.16, 76.90, 51.79, 35.25.



5. HRMS spectra of final compounds

Compound 30

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

1399 formula(e) evaluated with 8 results within limits (all results (up to 1000) for each mass)


Elements Used:

C: 9-35 H: 0-66 N: 0-10 O: 0-17 Na: 0-1 S: 0-1

Taus2-FL-R-NH2

PK HendrisW Taus2-FL-R-NH2 73 (1.754) Cm (73:75)

1: TOF MS ES+
7.35e+003



Compound 31

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 11.0 PPM / DBE: min = -1.5, max = 120.0^a

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

398 formula(e) evaluated with 7 results within limits (all results up to 1000) for each mass


Elements Used:

C: 0-25 H: 0-25 N: 0-10 O: 0-7 Na: 0-1 S: 1-1

Tau2,FL,OMe


PK HendrisW Tau2_FL_OMe 53 (1.275) AM2 (Ar,10000.0,0.00,0.00); ABS; Crm (52:53)

1: TOF MS ES+
5.15e+003



Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
339.1023	339.1028	-0.5	-1.5	12.5	123.1	4.2	C16 H15 N6 O S + ✓
	339.1031	-0.8	-2.4	8.5	121.8	2.9	C18 H20 O3 Na S
	339.1015	0.8	2.4	7.5	124.2	5.3	C15 H19 N2 O5 S
	339.1004	1.9	5.6	9.5	125.2	6.4	C14 H16 N6 O Na S
	339.1055	-3.2	-9.4	11.5	119.0	0.1	C20 H19 O3 S
	339.0991	3.2	9.4	4.5	126.2	7.3	C13 H20 N2 O5 Na S
	339.0988	3.5	10.3	8.5	127.0	8.1	C11 H15 N8 O3 S

Compound 32



Compound 64

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 6.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

2323 formula(e) evaluated with 12 results within limits (up to 20 closest results for each mass)


Elements Used:

C: 11-44 H: 0-99 N: 0-11 O: 0-11 F: 0-3 S: 0-1

WH-12 Tau

PK Hendris WH-12 Tau 37 (0.904) Cr (37:38)

1: TOF MS ES+
7.13e+002



Minimum: -1.5
Maximum: 55.0 6.0 120.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
341.0887	341.0886	0.1	0.3	12.5	195.2	2.3	C16 H13 N4 O5
	341.0884	0.3	0.9	3.5	194.7	1.8	C12 H18 O10 F
	341.0890	-0.3	-0.9	17.5	195.2	2.3	C22 H11 N2 F2
	341.0884	0.3	0.9	8.5	196.6	3.7	C14 H15 N4 O2
	341.0895	-0.8	-2.3	4.5	196.1	3.3	F2 S
	341.0897	-1.0	-2.9	8.5	194.8	1.9	C11 H16 N4 O3
	341.0899	-1.2	-3.5	17.5	195.3	2.4	F3 S
	341.0873	1.4	4.1	7.5	195.2	2.3	C15 H17 O9
341.0872	1.5	4.4	12.5	197.0	4.1	C17 H14 N4 O F	
	341.0902	-1.5	-4.4	13.5	194.9	2.0	S
	341.0870	1.7	5.0	3.5	196.3	3.5	C19 H12 N2 O
	341.0906	-1.9	-5.6	2.5	195.7	2.8	F3
							C13 H19 O6 F2
							S
							C12 H21 O9 S

Compound 65

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

2591 formula(e) evaluated with 10 results within limits (up to 20 closest results for each mass)


Elements Used:

C: 11-44 H: 0-99 N: 0-11 O: 0-11 F: 0-3 S: 0-1

WH-20 Tau

PK Hendris WH-20 Tau 39 (0.938) Crn (39:44)

1: TOF MS ES+
1.02e+004



Minimum: -1.5
Maximum: 55.0 5.0 120.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
355.1037	355.1038	-0.1	-0.3	-0.5	270.5	3.9	C11 H22 O7 F3
	355.1040	-0.3	-0.8	8.5	269.7	3.1	C15 H17 N4 O2
	355.1041	-0.4	-1.1	3.5	269.0	2.4	C13 H20 O10 F
	355.1042	-0.5	-1.4	12.5	268.3	1.7	C17 H15 N4 O5
	355.1029	0.8	2.3	7.5	268.5	1.9	C16 H19 O9
355.1029	0.8	2.3	12.5	269.2	2.7	C18 H16 N4 O F	
						S	
	355.1047	-1.0	-2.8	17.5	267.9	1.3	C23 H13 N2 F2
	355.1027	1.0	2.8	3.5	269.9	3.3	C14 H21 O6 F2
						S	
	355.1052	-1.5	-4.2	4.5	270.3	3.7	C12 H18 N4 O3
						F3 S	
	355.1054	-1.7	-4.8	8.5	268.8	2.2	C14 H16 N4 O6
						F	

Compound 66

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 4.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

2323 formula(e) evaluated with 8 results within limits (up to 20 closest results for each mass)


Elements Used:

C: 11-44 H: 0-99 N: 0-11 O: 0-11 F: 0-3 S: 0-1

WH-21 Tau

PK Hendris WH-21 Tau 124 (2.958) Cm (124:126)

1: TOF MS ES+
2.70e+002



Minimum:

Maximum: 55.0 4.0 -1.5 120.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
341.0862	341.0862	0.0	0.0	9.5	133.3	5.1	C14 H12 N4 O3 F3
341.0861	341.0861	0.1	0.3	16.5	130.6	2.4	C20 H13 N4 S
341.0859	341.0859	0.3	0.9	7.5	129.0	0.8	C16 H18 O5 F S
341.0859	341.0859	0.3	0.9	13.5	132.9	4.7	C12 H9 N10 O3
341.0870	341.0870	-0.8	-2.3	3.5	129.4	1.2	C13 H19 O6 F2 S
341.0872	341.0872	-1.0	-2.9	12.5	130.2	2.0	C17 H14 N4 O F S
341.0873	341.0873	-1.1	-3.2	7.5	133.0	4.9	C15 H17 O9
341.0850	341.0850	1.2	3.5	13.5	133.2	5.0	C17 H11 N4 O2 F2

Compound 67

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 4.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

3312 formula(e) evaluated with 16 results within limits (up to 20 closest results for each mass)


Elements Used:

C: 11-44 H: 0-99 N: 0-11 O: 0-11 F: 0-3 S: 0-1

WH-14 Tau

PK Hendris WH-14 Tau 29 (0.708) Cm (29:30)

1: TOF MS ES+
3.80e+002



Minimum: -1.5
Maximum: 55.0 4.0 120.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
391.0838	391.0838	0.0	0.0	16.5	62.8	3.5	C16 H11 N10 O
	391.0836	0.2	0.5	7.5	62.8	3.4	S
	391.0840	-0.2	-0.5	12.5	62.8	3.4	C12 H16 N6 O6
	391.0841	-0.3	-0.8	7.5	61.4	2.0	F S
	391.0843	-0.5	-1.3	16.5	61.9	2.6	C18 H14 N4 O
	391.0831	0.7	1.8	20.5	62.4	3.1	F3 S
	391.0829	0.9	2.3	11.5	62.0	2.7	C16 H17 O9 F2
	391.0829	0.9	2.3	16.5	63.2	3.9	C20 H12 N4 O4
	391.0827	1.1	2.8	7.5	63.1	3.8	F
	391.0849	-1.1	-2.8	12.5	62.9	3.5	C23 H11 N4 O3
	391.0827	1.1	2.8	13.5	61.3	2.0	C19 H16 O8 F
	391.0850	-1.2	-3.1	7.5	61.1	1.8	C21 H13 N4 F2
	391.0825	1.3	3.3	11.5	63.3	4.0	S
	391.0852	-1.4	-3.6	3.5	61.2	1.9	C11 H15 N6 O10
	391.0852	-1.4	-3.6	10.5	63.3	3.9	C15 H15 N6 O5
	391.0823	1.5	3.8	2.5	63.4	4.1	C13 H18 O10 F3
							C19 H19 O7 S
							C11 H20 N2 O10
							F S

Compound 68

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

3590 formula(e) evaluated with 20 results within limits (up to 20 closest results for each mass)


Elements Used:

C: 11-44 H: 0-99 N: 0-11 O: 0-11 F: 0-3 S: 0-1

WH-19 Tau

PK Hendris WH-19 Tau 169 (4.020) Cr (169:170)

1: TOF MS ES+
4.16e+003



Minimum:

Maximum:

55.0 5.0 -1.5
120.0 12.5

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
405.1013	405.1012	0.1	0.2	21.5	91.9	7.0	C22 H10 N8 F
	405.1011	0.2	0.5	12.5	91.0	6.2	C18 H15 N4 O5
	405.1017	-0.4	-1.0	8.5	90.9	6.1	C11 H15 N10 O3
	405.1009	0.4	1.0	3.5	90.7	5.9	C14 H20 O10 F3
	405.1008	0.5	1.2	10.5	86.8	2.0	C20 H21 O7 S
	405.1019	-0.6	-1.5	6.5	85.1	0.3	C17 H22 O8 F S
	405.1006	0.7	1.7	12.5	89.6	4.8	C14 H14 N10 O2
	405.1020	-0.7	-1.7	12.5	91.6	6.8	C13 H13 N10 O6
	405.1006	0.7	1.7	7.5	91.6	6.8	C12 H17 N6 O10
	405.1021	-0.8	-2.0	15.5	88.7	3.9	C21 H17 N4 O3
	405.1022	-0.9	-2.2	8.5	91.3	6.5	C15 H16 N4 O6
	405.1024	-1.1	-2.7	17.5	91.8	7.0	C19 H11 N8 O
	405.0999	1.4	3.5	16.5	91.9	7.1	C21 H14 N4 O4
	405.1028	-1.5	-3.7	24.5	93.2	8.4	C29 H13 N2 O
405.0997	1.6	3.9	12.5	89.9	5.1	C19 H16 N4 O	
	405.0997	1.6	3.9	7.5	91.3	6.5	C17 H19 O9 F2
	405.0995	1.8	4.4	9.5	93.7	8.9	C11 H12 N10 O4
	405.0995	1.8	4.4	16.5	90.5	5.7	C17 H13 N10 O
	405.1031	-1.8	-4.4	2.5	88.5	3.7	C14 H23 O9 F2
	405.1033	-2.0	-4.9	11.5	87.7	2.9	C18 H18 N4 O4

Compound 69

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 19.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

644 formula(e) evaluated with 9 results within limits (up to 20 closest results for each mass)


Elements Used:

C: 11-44 H: 0-99 N: 0-11 O: 0-11 S: 0-1

WH-13 Tau

PK Hendris WH-13 Tau 33 (0.796) Cm (33)

1: TOF MS ES+
7.08e+002



Minimum: -1.5
Maximum: 55.0 19.0 120.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
323.0981	323.0978	0.3	0.9	3.5	87.5	2.1	C12 H19 O10
	323.0992	-1.1	-3.4	8.5	87.7	2.3	C13 H15 N4 O6
	323.0967	1.4	4.3	12.5	86.7	1.3	C17 H15 N4 O S
	323.1005	-2.4	-7.4	13.5	88.2	2.8	C14 H11 N8 O2
	323.0953	2.8	8.7	7.5	86.6	1.2	C16 H19 O5 S
	323.0933	4.8	14.9	17.5	89.7	4.3	C20 H11 N4 O
	323.1032	-5.1	-15.8	12.5	90.2	4.8	C18 H15 N2 O4
	323.0926	5.5	17.0	8.5	88.3	2.9	C12 H15 N6 O3
	323.1039	-5.8	-18.0	8.5	88.4	2.9	S
							C11 H15 N8 O2
							S

Compound 70

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 6.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

2558 formula(e) evaluated with 15 results within limits (up to 20 closest results for each mass)


Elements Used:

C: 11-44 H: 0-99 N: 0-11 O: 0-11 F: 0-3 S: 0-1

WH-09 Tau

PK Hendris WH-09 Tau 49 (1.187) Cm (44:51)

1: TOF MS ES+
1.56e+004



Minimum: -1.5
Maximum: 120.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
353.1070	353.1070	0.0	0.0	3.5	179.5	3.9	C14 H22 O7 F S
	353.1072	-0.2	-0.6	12.5	179.5	3.9	C18 H17 N4 O2 S
353.1073	353.1073	-0.3	-0.8	5.5	177.7	2.1	C12 H16 N4 O5 F3
353.1075	353.1075	-0.5	-1.4	14.5	177.6	2.0	C16 H11 N8 F2
353.1061	353.1061	0.9	2.5	9.5	177.9	2.3	C15 H15 N4 O4 F2
353.1079	353.1079	-0.9	-2.5	21.5	178.8	3.2	C26 H13 N2 F S
353.1059	353.1059	1.1	3.1	0.5	178.2	2.6	C11 H20 O9 F3
353.1059	353.1059	1.1	3.1	7.5	179.5	3.9	C17 H21 O6 S
353.1082	353.1082	-1.2	-3.4	-0.5	179.5	3.9	C11 H23 O8 F2 S
353.1057	353.1057	1.3	3.7	9.5	179.2	3.6	C11 H14 N10 O F S
353.1084	353.1084	-1.4	-4.0	8.5	179.4	3.8	C15 H18 N4 O3 F S
353.1084	353.1084	-1.4	-4.0	3.5	178.6	3.0	C13 H21 O11
353.1086	353.1086	-1.6	-4.5	10.5	177.1	1.5	C13 H12 N8 O F3
353.1050	353.1050	2.0	5.7	13.5	178.2	2.6	C18 H14 N4 O3 F
353.1090	353.1090	-2.0	-5.7	17.5	178.6	3.0	C23 H14 N2 O F

Compound 71

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

1080 formula(e) evaluated with 7 results within limits (all results (up to 1000) for each mass)


Elements Used:

C: 9-35 H: 0-20 N: 0-10 O: 0-17 Na: 0-1 S: 0-1

Taus-FL-HO2-OMe

PK HendrisW Taus-FL-HO2-OMe 58 (1.399) Cm (55:58)

1: TOF MS ES+
3.55e+003



Minimum:

Maximum:

55.0 5.0

-1.5

120.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
368.0829	368.0829	0.0	0.0	4.5	203.4	2.7	C12 H18 N O12
368.0832	368.0832	-0.3	-0.8	11.5	203.0	2.3	C12 H11 N9 O4
368.0824	0.5	1.4	22.5	201.9	1.2		Na
368.0834	-0.5	-1.4	14.5	202.5	1.8		C25 H10 N3 O
368.0818	1.1	3.0	6.5	203.8	3.1		C20 H15 N3 O
368.0817	1.2	3.3	13.5	202.7	2.0		Na S
368.0842	-1.3	-3.5	9.5	202.4	1.7		C11 H15 N5 O8

Compound 72

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 6.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

3137 formula(e) evaluated with 15 results within limits (up to 20 closest results for each mass)


Elements Used:

C: 11-44 H: 0-99 N: 0-11 O: 0-11 F: 0-3 S: 0-1

WH-10 Tau

PK Hendris WH-10 Tau 40 (0.974) Cr (40:41)

1: TOF MS ES+
1.07e+003



Minimum: 378.3714 Maximum: 387.6744

Mass Calc. Mass mDa PPM DBE i-FIT i-FIT (Norm) Formula

382.0984	382.0985	-0.1	-0.3	9.5	139.7	2.1	C15 H17 N5 O4
	382.0983	0.1	0.3	0.5	140.1	2.4	F S C11 H22 N O9
	382.0988	-0.4	-1.0	11.5	140.3	2.7	F2 S C13 H11 N9 O2
	382.0980	0.4	1.0	22.5	140.3	2.6	F3 C26 H12 N3 O
	382.0992	-0.8	-2.1	18.5	141.3	3.6	C23 H13 N3 O2
	382.0976	0.8	2.1	15.5	140.1	2.4	F2 C16 H10 N9 O
	382.0974	1.0	2.6	6.5	140.3	2.6	F3 C12 H15 N5 O6
	382.0974	1.0	2.6	13.5	139.6	1.9	C18 H16 N5 O3
	382.0972	1.2	3.1	4.5	139.8	2.2	S C14 H21 N O8 F
	382.0997	-1.3	-3.4	5.5	140.8	3.1	C12 H18 N5 O5
	382.0999	-1.5	-3.9	9.5	141.9	4.2	F2 S C14 H16 N5 O8
	382.0999	-1.5	-3.9	14.5	140.7	3.0	C16 H13 N9 F S
	382.0965	1.9	5.0	19.5	140.7	3.1	C19 H9 N9 F
	382.1003	-1.9	-5.0	14.5	142.6	5.0	C20 H14 N3 O3
	382.0963	2.1	5.5	10.5	140.9	3.3	F2 C15 H14 N5 O5

Compound 73

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 6.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

2466 formula(e) evaluated with 13 results within limits (up to 20 closest results for each mass)


Elements Used:

C: 11-44 H: 0-99 N: 0-11 O: 0-11 F: 0-3 S: 0-1

WH-11 Tau

PK Hendris WH-11 Tau 34 (0.833) Cm (31:36)

1: TOF MS ES+
5.85e+003



Minimum: 344.0
Maximum: 362.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
348.0926	348.0929	-0.3	-0.9	1.5	171.1	10.3	C ₁₁ H ₂₀ N ₀ O ₇
	348.0930	-0.4	-1.1	10.5	170.6	9.8	F ₂ S
	348.0931	-0.5	-1.4	5.5	167.3	6.5	C ₁₅ H ₁₅ N ₅ O ₂
	348.0920	0.6	1.7	7.5	162.7	1.9	F ₃
	348.0933	-0.7	-2.0	12.5	161.0	0.2	C ₁₃ H ₉ N ₉ F ₃
	348.0919	0.7	2.0	14.5	170.5	9.8	C ₁₈ H ₁₄ N ₅ O ₁ S
	348.0917	0.9	2.6	5.5	171.0	10.2	C ₁₄ H ₁₉ N ₀ O ₆ F ₃
	348.0937	-1.1	-3.2	19.5	169.6	8.8	S
	348.0942	-1.6	-4.6	6.5	171.2	10.4	C ₂₃ H ₁₁ N ₃ F
	348.0944	-1.8	-5.2	10.5	166.4	5.7	C ₁₂ H ₁₆ N ₅ O ₃
	348.0908	1.8	5.2	11.5	164.1	3.4	F ₂ S
	348.0906	2.0	5.7	2.5	166.6	5.8	C ₁₄ H ₁₄ N ₅ O ₆
	348.0906	2.0	5.7	9.5	171.6	10.8	C ₁₅ H ₁₂ N ₅ O ₃
							F ₂
							C ₁₁ H ₁₇ N ₀ O ₈
							F ₃
							C ₁₇ H ₁₈ N ₀ O ₅ S

Compound 74

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 15.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

782 formula(e) evaluated with 12 results within limits (up to 20 closest results for each mass)


Elements Used:

C: 11-44 H: 0-99 N: 0-11 F: 0-3 Na: 0-1 S: 0-2

WH-17 Tau

PK Hendris WH-17 Tau 122 (2.904) Cm (122:123)

1: TOF MS ES+
1.55e+003



Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
325.0933	325.0933	0.0	0.0	4.5	50.8	1.9	C12 H19 N4 F
	325.0929	0.4	1.2	10.5	50.9	2.0	Na S2
	325.0926	0.7	2.2	14.5	50.9	2.0	C17 H13 N2 F3
	325.0923	1.0	3.1	12.5	51.1	2.1	Na
	325.0950	-1.7	-5.2	17.5	51.4	2.4	C17 H9 N8
	325.0953	-2.0	-6.2	13.5	51.5	2.5	C19 H12 N2 F3
	325.0957	-2.4	-7.4	7.5	51.6	2.7	C14 H18 N4 F
							S2
	325.0960	-2.7	-8.3	9.5	51.6	2.7	C12 H14 N8 Na
	325.0962	-2.9	-8.9	5.5	51.8	2.8	S
	325.0899	3.4	10.5	9.5	52.1	3.2	C14 H17 N2 F3
	325.0896	3.7	11.4	7.5	52.4	3.4	Na S
	325.0889	4.4	13.5	17.5	52.7	3.8	C15 H15 N4 F
							C17 H19 F2 S2
							C20 H10 N4 F

Compound 75

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 11.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

1022 formula(e) evaluated with 6 results within limits (up to 20 closest results for each mass)


Elements Used:

C: 15-44 H: 0-66 N: 0-11 O: 0-11 F: 0-1 S: 0-1

Tau R=Me n=2 R=F

PK Hendris Tau R-Me n-2 R-F 24 (0.584) Cm (23:24)

1: TOF MS ES+
2.94e+002
353.2699



Minimum: -1.5
Maximum: 55.0 11.0 120.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
339.1093	339.1093	0.0	0.0	12.5	113.6	3.3	C17 H15 N4 O4
339.1080	339.1080	1.3	3.8	7.5	113.2	2.9	C16 H19 O8
339.1080	339.1080	1.3	3.8	12.5	111.5	1.2	C18 H16 N4 F S
339.1107	339.1107	-1.4	-4.1	17.5	114.0	3.7	C18 H11 N8
339.1118	339.1118	-2.5	-7.4	13.5	113.5	3.2	C15 H12 N8 O F
339.1066	339.1066	2.7	8.0	7.5	110.9	0.6	C17 H20 O4 F S

Compound 76

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

4015 formula(e) evaluated with 21 results within limits (up to 15 closest results for each mass)


Elements Used:

C: 11-44 H: 0-99 N: 0-11 O: 0-11 F: 0-3 S: 0-2

WH-16 Tau

PK Hendris WH-16 Tau 32 (0.779) Cm (32:33)


1: TOF MS ES+
1.97e+003




Minimum: -1.5
Maximum: 55.0 5.0 120.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
375.0898	375.0896	0.2	0.5	1.5	106.3	6.9	C11 H23 N2 O8
	375.0900	-0.2	-0.5	12.5	99.7	0.4	S2
	375.0900	-0.2	-0.5	6.5	105.3	6.0	C13 H12 N10 O
	375.0901	-0.3	-0.8	7.5	105.2	5.9	F8
	375.0902	-0.4	-1.1	10.5	102.0	2.6	C11 H15 N6 O9
	375.0903	-0.5	-1.3	3.5	105.4	6.1	C19 H19 O6 S
	375.0893	0.5	1.3	16.5	106.0	6.7	C13 H18 O9 F3
	375.0905	-0.7	-1.9	12.5	105.7	6.4	C20 H12 N4 O3
	375.0891	0.7	1.9	12.5	102.6	3.2	F2
	375.0891	0.7	1.9	7.5	104.7	5.4	C18 H14 N4 F3
	375.0889	0.9	2.4	16.5	103.4	4.1	C16 H17 O8 F2
	375.0889	0.9	2.4	10.5	106.7	7.4	C16 H11 N10 S
	375.0909	-1.1	-2.9	6.5	105.8	6.5	C20 H20 O2 F
	375.0887	1.1	2.9	7.5	101.2	1.8	S2
	375.0912	-1.4	-3.7	2.5	105.8	6.5	C12 H19 N6 O4
							C12 H16 N6 O5
							C14 H22 O4 F3
							S2

Compound 89



Compound 90



Compound 91

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 6.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

1641 formula(e) evaluated with 8 results within limits (all results (up to 1000) for each mass)


Elements Used:

C: 9-35 H: 0-66 N: 0-10 O: 0-17 Na: 0-1 S: 0-1

Taus3-FL-7-ol


PK HendrisW Taus3-FL-7-ol 124 (2.958) Cm (123:125)

1: TOF MS ES+
2.84e+003



Minimum:	-1.5						
Maximum:	55.0	6.0	120.0				
Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
347.1556	347.1556	0.0	0.0	6.5	117.2	2.0	C12 H20 N8 O3
	347.1558	-0.2	-0.6	9.5	117.9	2.7	Na C20 H24 N2 Na
	347.1553	0.3	0.9	-0.5	117.0	1.8	S C12 H27 O11
	347.1548	0.8	2.3	17.5	117.4	2.2	C25 H19 N2
	347.1567	-1.1	-3.2	4.5	117.0	1.8	C13 H23 N4 O7
	347.1543	1.3	3.7	1.5	117.1	1.9	C11 H24 N4 O7
	347.1542	1.4	4.0	8.5	118.0	2.8	Na C17 H23 N4 O2 ✓
	347.1540	1.6	4.6	5.5	117.2	2.0	S C9 H19 N10 O5

Compound 92



Compound 93

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 10.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

1268 formula(e) evaluated with 11 results within limits (up to 25 closest results for each mass)


Elements Used:

C: 9-39 H: 0-75 N: 0-10 O: 0-12 Na: 0-1 S: 0-1

Tau3-FL-Ethyldiol

PK Hendris Tau3-FL-Ethyldiol 237 (5.613) Cm (237:241)

1: TOF MS ES+
8.95e+002



Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
321.1035	321.1036	-0.1	-0.3	6.5	203.2	4.9	C9 H14 N8 O4 Na
321.1033	0.2	0.6	-0.5	203.5	5.2	C9 H21 O12'	
321.1038	-0.3	-0.9	9.5	200.2	1.9	C17 H18 N2 O Na S	
321.1028	0.7	2.2	17.5	199.8	1.5	C22 H13 N2 O	
321.1046	-1.1	-3.4	4.5	203.1	4.8	C10 H17 N4 O8	
321.1021	1.4	4.4	8.5	201.2	2.8	C14 H17 N4 O3 S ✓	
321.1060	-2.5	-7.8	9.5	202.8	4.5	C11 H13 N8 O4	
321.1062	-2.7	-8.4	12.5	199.2	0.9	C19 H17 N2 O S	
321.1008	2.7	8.4	3.5	202.0	3.7	C13 H21 O7 S	
321.1063	-2.8	-8.7	5.5	202.7	4.4	C13 H18 N2 O6 Na	
321.1004	3.1	9.7	14.5	200.6	2.3	C20 H14 N2 O Na	

Compound 109

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

875 formula(e) evaluated with 3 results within limits (all results (up to 1000) for each mass)


Elements Used:

C: 15-50 H: 3-70 N: 0-10 O: 0-11 Na: 0-1 S: 0-2

Tau2G n-0 R-MeN

PK Hendris Tau2G n-0 R-MeN 21 (0.513) Cm (21)


1: TOF MS ES+
8.26e+003




Minimum: -1.5
Maximum: 55.0 5.0 120.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
300.0814	300.0813	0.1	0.3	19.5	136.2	10.8	C23 H10 N
	300.0807	0.7	2.3	10.5	127.0	1.5	C15 H14 N3 O2 ✓
	300.0823	-0.9	-3.0	11.5	125.7	0.3	S C18 H15 N Na S

Compound 110



Compound 111



Compound 112

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

3636 formula(e) evaluated with 9 results within limits (up to 15 closest results for each mass)


Elements Used:

C: 12-55 H: 3-70 N: 0-10 O: 0-15 F: 0-3 Na: 0-1 S: 0-2

Tau2G-FL-03

PK Hendris Tau2G-FL-03 37 (0.904) Cm (35:38)

1: TOF MS ES+
7.69e+003



Minimum:	-1.5						
Maximum:	55.0	5.0	120.0				
Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
	304.0556	0.0	0.0	10.5	160.9	3.8	C14 H11 N3 O2 F S
	304.0554	0.2	0.7	6.5	162.6	5.5	C12 H15 N3 O Na S2
	304.0559	-0.3	-1.0	12.5	158.5	1.4	C12 H7 N7 O2 Na
	304.0559	-0.3	-1.0	12.5	159.0	1.8	C12 H5 N7 F3
	304.0561	-0.5	-1.6	8.5	159.0	1.8	C14 H10 N O2 F3 Na
	304.0550	0.6	2.0	12.5	160.8	3.7	C17 H9 N O F2 Na
	304.0563	-0.7	-2.3	19.5	163.0	5.8	C22 H7 N F
	304.0545	1.1	3.6	14.5	161.6	4.5	C17 H10 N3 O S
	304.0570	-1.4	-4.6	10.5	158.2	1.0	C13 H10 N3 O6

Compound 113

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 9.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

2158 formula(e) evaluated with 10 results within limits (up to 15 closest results for each mass)


Elements Used:

C: 12-55 H: 3-70 N: 0-10 O: 0-15 F: 0-1 Na: 0-1 S: 0-2

Tau2G-FL-01

PK Hendris Tau2G-FL-01 37 (0.904)

1: TOF MS ES+
3.98e+002



Minimum:

Maximum:

55.0 9.0 -1.5
120.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
304.0567	304.0570	-0.3	-1.0	10.5	67.6	2.0	C13 H10 N3 O6
	304.0563	0.4	1.3	19.5	70.6	5.0	C22 H7 N F
	304.0572	-0.5	-1.6	11.5	68.0	2.4	C17 H12 N F Na
	304.0559	0.8	2.6	12.5	67.8	2.2	S
	304.0556	1.1	3.6	10.5	66.4	0.8	C12 H7 N7 O2
							Na
							C14 H11 N3 O2
	304.0578	-1.1	-3.6	9.5	69.6	4.0	F S
							C14 H14 N3 O
	304.0554	1.3	4.3	6.5	68.7	3.1	S2
							C12 H15 N3 O
	304.0583	-1.6	-5.3	15.5	69.1	3.5	Na S2
	304.0586	-1.9	-6.2	11.5	69.4	3.8	C14 H6 N7 O2
							C16 H11 N O4
	304.0545	2.2	7.2	14.5	68.3	2.7	Na
							C17 H10 N3 O S

Compound 114

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

3636 formula(e) evaluated with 10 results within limits (up to 15 closest results for each mass)


Elements Used:

C: 12-55 H: 3-70 N: 0-10 O: 0-15 F: 0-3 Na: 0-1 S: 0-2

Tau2G-FL-02


PK Hendris Tau2G-FL-02 36 (0.867) Cm (36:37)

1: TOF MS ES+
3.03e+003



Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
304.0547	304.0545	0.2	0.7	14.5	153.1	3.2	C17 H10 N3 O S
	304.0550	-0.3	-1.0	12.5	152.6	2.7	C17 H9 N O F2
	304.0554	-0.7	-2.3	6.5	155.1	5.2	C12 H15 N3 O
	304.0558	0.9	3.0	16.5	153.9	4.0	Na S2
304.0556	304.0556	-0.9	-3.0	10.5	152.4	2.5	C20 H8 N F Na
	304.0559	-1.2	-3.9	12.5	152.0	2.0	C14 H11 N3 O2 F
	304.0559	-1.2	-3.9	12.5	152.8	2.9	C12 H7 N7 O2
304.0534	1.3	4.3	11.5	151.2	1.2	C14 H8 N3 O3	
	304.0561	-1.4	-4.6	8.5	152.4	2.5	F2
	304.0532	1.5	4.9	7.5	151.5	1.6	C14 H10 N O2
							F Na
							C12 H12 N3 O2
							Na S

Compound 115



Compound 116

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

977 formula(e) evaluated with 3 results within limits (all results (up to 1000) for each mass)


Elements Used:

C: 15-50 H: 3-70 N: 0-10 O: 0-11 Na: 0-1 S: 0-2

Tau2GFL n-1 R-MeN

PK Hendris Tau2GFL n-1 R-MeN 60 (1.434) Cm (60:62)

1: TOF MS ES+
3.67e+002



Minimum:

Maximum:

55.0 5.0

-1.5

120.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
------	------------	-----	-----	-----	-------	--------------	---------

314.0974	314.0970	0.4	1.3	19.5	146.9	0.3	C24 H12 N
	314.0979	-0.5	-1.6	11.5	148.9	2.3	C19 H17 N Na S
	314.0963	1.1	3.5	10.5	148.6	2.0	C16 H16 N3 O2 S

Compound 117

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

873 formula(e) evaluated with 3 results within limits (all results (up to 1000) for each mass)


Elements Used:

C: 15-50 H: 3-70 N: 0-10 O: 0-11 Na: 0-1 S: 0-2

Tau2GFL n-1 R-H

PK Hendris Tau2GFL n-1 R-H 58 (1.399) Cm (58:59)

1: TOF MS ES+
1.57e+003



Minimum: -1.5

Maximum: 55.0 5.0 120.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
299.0849	299.0854	-0.5	-1.7	10.5	146.1	1.1	C16 H15 N2 O2 S
299.0861		-1.2	-4.0	19.5	145.9	0.9	C24 H11
299.0837		1.2	4.0	16.5	146.3	1.3	C22 H12 Na

Compound 118

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

973 formula(e) evaluated with 3 results within limits (all results (up to 1000) for each mass)


Elements Used:

C: 15-50 H: 3-70 N: 0-10 O: 0-11 Na: 0-1 S: 0-2

Tau2GFL n-1 Rr2-Me

PK Hendris Tau2GFL n-1 Rr2-Me 45 (1.079) Cm (45:46)

1: TOF MS ES+
3.91e+004



Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
313.1017	313.1017	0.0	0.0	19.5	198.7	13.4	C25 H13
	313.1011	0.6	1.9	10.5	186.6	1.2	C17 H17 N2 O2 ✓ S
	313.1027	-1.0	-3.2	11.5	185.7	0.3	C20 H18 Na S

Compound 119

S121

Elemental Composition Report**Page 1****Single Mass Analysis**

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 120.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions


1855 formula(e) evaluated with 5 results within limits (all results (up to 1000) for each mass)

Elements Used:

C: 15-50 H: 3-70 N: 0-10 O: 0-11 F: 0-1 Na: 0-1 S: 0-2

Tau2GFL n-1 R-F

PK Hendris Tau2GFL n-1 R-F 78 (1.859) Crn (78:79)

1: TOF MS ES+
1.18e+003

Minimum:				-1.5			
Maximum:	55.0	5.0	120.0				
Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
317.0762	317.0760	0.2	0.6	10.5	115.0	0.8	C16 H14 N2 O2 F S
	317.0767	-0.5	-1.6	19.5	116.7	2.5	C24 H10 F
	317.0774	-1.2	-3.8	10.5	116.3	2.1	C15 H13 N2 O6
	317.0749	1.3	4.1	14.5	116.1	1.9	C19 H13 N2 O S
	317.0776	-1.4	-4.4	11.5	115.9	1.7	C19 H15 F Na S

Compound 120

S122

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 120.0
 Element prediction: Off
 Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

4107 formula(e) evaluated with 12 results within limits (up to 15 closest results for each mass)


Elements Used:

C: 12-55 H: 3-70 N: 0-10 O: 0-15 F: 0-3 Na: 0-1 S: 0-2

Tau2G-FL-05

PK Hendris Tau2G-FL-05 29 (0.708) Cm (28:30)

1: TOF MS ES+
 2.35e+003




Minimum: -1.5
 Maximum: 55.0 5.0 120.0


Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
317.0747	317.0749	-0.2	-0.6	7.5	134.1	1.5	C13 H12 N2 O4
	317.0749	-0.2	-0.6	14.5	138.5	5.8	F3
	317.0750	-0.3	-0.9	7.5	133.2	0.6	C19 H13 N2 O S
							C13 H14 N2 O6
							Na
							Na
	317.0742	0.5	1.6	16.5	138.8	6.2	C22 H11 F Na
	317.0754	-0.7	-2.2	12.5	137.8	5.1	C19 H12 O F2
							Na
							C12 H9 N6 F3
	317.0738	0.9	2.8	9.5	135.4	2.8	Na
	317.0738	0.9	2.8	11.5	136.0	3.4	C16 H11 N2 O3
							F2
	317.0736	1.1	3.5	7.5	136.5	3.9	C14 H15 N2 O2
							F Na S
	317.0758	-1.1	-3.5	6.5	139.6	7.0	C14 H18 N2 O
							Na S2
	317.0760	-1.3	-4.1	10.5	137.8	5.2	C16 H14 N2 O2
							F S ✓
	317.0733	1.4	4.4	11.5	135.6	3.0	C12 H10 N8 F S
	317.0763	-1.6	-5.0	12.5	136.4	3.8	C14 H8 N6 F3


Compound 127

S123



















Compound 128











6. Physicochemical properties of several ligand candidates

Structure	clogP ^a	HBA ^a	HBD ^a	PSA ^a	logBB ^b
 30	2.35	7	2	91.76	-0.862
 31	2.73	7	1	77.76	-0.597
 32	2.19	7	2	88.76	-0.842
 64	3.87	5	0	52.84	-0.005
 67	4.82	5	0	52.84	0,090
 69	3.71	5	0	52.84	-0.008
 70	3.44	6	1	73.07	-0,420

	3.67	8	0	98.67	-0.763
	3.88	8	0	98.67	-0.732
	3.46	6	0	76.64	-0.469
	4.47	4	0	43.61	0.173
	1.48	6	1	73.07	-0.717
	1.75	6	1	73.07	-0.674
	3.54	6	1	73.07	-0.404
	4.05	6	1	73.07	-0.327
	1.37	7	1	82.31	-0.871

	1.74	5	1	64.12	-0,546
	2.76	5	1	75.02	-0.552
	2.36	5	2	71.45	-0.560
	3.32	5	0	72.22	-0.425
	3.70	4	0	48.43	-0.015
	4.46	4	0	48.43	0.100
Required ^c	≤5	≤7	≤3	≤90	>-1

^aCalculated using Cheminformatics (<http://www.molinspiration.com/>).

^bLogBB = $-0.0148 \times \text{TPSA} + 0.152 \times \text{cLogP} + 0.139$.¹⁴

^cParameters required to fulfill physiochemical properties (drug-like molecules) according to Lipinski's Rules.¹⁵

6. References

1. P. T. S. Lau and T. E. Gomp, *J. Org. Chem.*, 1970, **35**, 4103-4108.
2. G. Colombano, C. Albani, G. Ottonello, A. Ribeiro, R. Scarpelli, G. Tarozzo, J. Daglian, K. M. Jung, D. Piomelli and T. Bandiera, *Chem. Med. Chem.*, 2015, **10**, 380-395.
3. S. Lal, H. S. Rzepa and S. Díez-González, *Catal.*, 2014, **4**, 2274-2287.
4. T. Suzuki, Y. Ota, M. Ri, M. Bando, A. Gotoh, Y. Itoh, H. Tsumoto, P. R. Tatum, T. Mizukami, H. Nakagawa, S. Iida, R. Ueda, K. Shirahige and N. Miyata, *J. Med. Chem.*, 2012, **55**, 9562-9575.
5. B. Ourri, O. Tillement, T. Tu, E. Jeanneau, U. Darbost and I. Bonnamour, *New. J. Chem.*, 2016, **40**, 9477-9485.
6. Y. Yan, T. M. Deaton, J. Zhang, H. He, J. Hayat, P. Pageni, K. Matyjaszewski and C. Tang, *Macromolecules.*, 2015, **48**, 1644-1650.
7. T. Masuya, M. Murai, H. Morisaka and H. Miyoshi, *Biochemistry.*, 2014, **53**, 7816-7823.
8. L. Diaz, J. Casas, J. Bujons, A. Llebaria and A. Delgado, *J. Med. Chem.*, 2011, **54**, 2069-2079.
9. R. Sommer, J. Neres, J. Piton, N. Dhar, A. van der Sar, R. Mukherjee, T. Laroche, P. J. Dyson, J. D. McKinney, W. Bitter, V. Makarov and S. T. Cole, *Chem. Biol.*, 2018, **13**, 3184-3192.
10. Y. Jia, H. Qin, N. Wang, Z. X. Jiang and Z. Yang, *J. Org. Chem.*, 2018, **83**, 2808-2817.
11. C. Dyrager, R. P. Vieira, S. Nyström, K. P. R. Nilsson and T. Storr, *New. J. Chem.*, 2017, **41**, 1566-1573.
12. G. C. Meroni, P.; Meda, C.; Maggi, A.; Santaniello, E, *Arkivoc.*, 2009, **11**, 22-30.
13. Z. J. Bin, L.; Wei, C.; Yunxia, W.; Zhen, S., *Chin. J. Chem.*, 2010, **28**, 111-114.
14. D.E. Clark., *J. Pharm. Sci.*, 1999, **88**, 815-821.
15. C.A. Lipinski., *Drug Discov. Today Technol.*, 2004, **1**, 337-341.